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ABSTRACT 
 
The presence of certain cancer-related genetic and epigenetic alterations in the tumor 
affect patients´ response to specific cancer therapies. The accurate screening of these 
predictive biomarkers in molecular diagnostics is important since it enables the tailoring 
of an optimal treatment based on molecular characteristics of the tumor. Depending on 
the type of gene alteration, a wide variety of methods could be applied in biomarker 
testing. Among the novel methods is next-generation sequencing (NGS) technology, 
enabling simultaneous detection of multiple alterations. The aim of this thesis was to 
analyze predictive or potentially predictive genetic and epigenetic alterations of diffuse 
gliomas and non-small cell lung cancer (NSCLC), and to evaluate the feasibility of 
pyrosequencing and targeted NGS in the detection of these alterations in formalin-fixed 
paraffin-embedded (FFPE) tumor tissue specimens.  
In Study I, we assessed the genetic and epigenetic profile of diffuse gliomas by applying 
methylation-specific pyrosequencing to detect MGMT promoter hypermethylation, array 
comparative genomic hybridization to detect chromosomal copy number alterations, and 
immunohistochemistry (IHC) to detect IDH1 mutation status. MGMT hypermethylation, 
IDH1 mutations, and losses of chromosome arms 1p and 19q were typical changes in 
oligodendroglial tumors (grades II-III), whereas losses of 9p and 10q were frequently 
seen in glioblastomas (grade IV). Furthermore, we detected significant associations of 1) 
MGMT hypermethylation with IDH1 mutations and loss of 19q, 2) unmethylated MGMT 
with losses of 9p and 10q and gain of 7p, 3) IDH1 mutations with MGMT 
hypermethylation, 1p loss, and combined loss of 1p/19q, and 4) non-mutated IDH1 with 
losses of 10q. Pyrosequencing proved to be a feasible method for determination of MGMT 
methylation status in FFPE sample material. 
In Studies II and III, we compared targeted NGS with fluorescence in situ hybridization, 
IHC, and real-time reverse-transcription PCR in the detection of ALK fusion (Study II), 
and with real-time PCR in the detection of EGFR, KRAS, and BRAF mutations (Study 
III). All analyses were successfully performed on all FFPE samples. A good concordance 
was observed between the results obtained by different methods, and targeted NGS also 
proved to be advantageous in the identification of novel and rare variants with a potential 
predictive value. 
In Study IV, we determined the frequency of ALK fusion in 469 Finnish NSCLC patients, 
and the association of ALK fusion with clinicopathological characteristics and with the 
presence of mutations in 22 other driver genes. We detected ALK fusion at a frequency 
of 2.3%, suggesting that it is a relatively rare alteration in Finnish NSCLC patients. The 
presence of ALK fusion was significantly linked to younger age and never-/ex-light 
smoking history. Although most of the ALK-positive tumors had adenocarcinoma 
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histology, also ALK-positive large cell carcinomas were detected. Characterization of 
ALK-positive cases by targeted NGS showed a coexistence of ALK fusion with mutations 
in MET, TP53, CTNNB1, and PIK3CA, but the value of these co-occurrences requires 
further examination. 
In conclusion, our studies indicate that certain genetic and epigenetic alterations occur 
together, and the simultaneous screening of multiple alterations may thus allow one to 
obtain a more comprehensive picture of the molecular background of the tumor, which 
could facilitate prediction of tumor behavior, prognosis, and treatment response. Our 
results show the feasibility of pyrosequencing and targeted NGS in FFPE tumor tissue 
material and also the advantages of targeted NGS over other commonly used methods in 
the detection of gene rearrangements and mutations, particularly the ability to 
simultaneously identify multiple alterations. 
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TIIVISTELMÄ 
 
Tiettyjen syöpään liityvien geneettisten ja epigeneettisten muutosten esiintyminen 
kasvaimissa vaikuttaa potilaan vasteeseen syöpähoidoille. Näiden hoitovastetta 
ennustavien, prediktiviisten biomarkkereiden tarkka seulonta molekyylidiagnostiikassa 
on tärkeää, sillä se mahdollistaa optimaalisen hoidon räätälöinnin kasvaimen 
molekulaaristen ominaisuuksien perusteella. Geenimuutoksesta riippuen 
biomarkkereiden testauksessa voidaan hyödyntää useita eri menetelmiä, joista uusimpien 
joukossa ovat lukuisten markkereiden samanaikaisen tutkimisen mahdollistavat uuden 
sukupolven sekvensointimenetelmät. Tämän väitöskirjatutkimuksen tavoitteena oli 
analysoida hoitovastetta ennustavia geneettisiä ja epigeneettisiä muutoksia glioomissa ja 
ei-pienisoluisessa keuhkosyövässä. Lisäksi työssä arvioitiin pyrosekvensoinnin ja 
kohdennetun uuden sukupolven sekvensoinnin soveltuvuutta näiden muutosten 
tunnistamiseen formaliiniin fiksoiduista ja parafiiniin valetuista (FFPE) 
kasvainkudosnäytteistä. 
Ensimmäisessä osatyössä tutkimme 51 glioomanäytettä määrittämällä niistä MGMT-
geenin säätelyalueen metyloitumisasteen pyrosekvensoinnilla, kromosomien 
kopiolukumäärämuutokset mikrosirupohjaisella vertailevalla genomisella 
hybridisaatiolla ja IDH1-geenin mutaatiostatuksen immunohistokemiallisella 
värjäyksellä. Tutkimuksessa havaitsimme vaihtelua tutkittujen biomarkkerien 
esiintymisessä eri glioomatyyppien välillä: MGMT-geenin metylaatio, IDH1-geenin 
mutaatiot sekä kromosomien 1p ja 19q puutokset olivat tyypillisiä muutoksia 
oligodendrogliaalisissa kasvaimissa (gradus II-III), kun taas kromosomien 9p ja 10q 
puutoksia nähtiin useammin glioblastoomissa (gradus IV). Lisäksi osoitimme, että 1) 
metyloitunut MGMT-geeni esiintyy usein yhdessä IDH1-geenin mutaation ja 
kromosomin 19q puutoksen kanssa, 2) metyloitumaton MGMT-geeni kromosomien 9p ja 
10q puutosten sekä kromosomin 7q monistuman kanssa 3) mutatoitunut IDH1-geeni 
metyloituneen MGMT-geenin sekä kromosomien 1p ja 1p/19q puutosten kanssa, sekä 4) 
mutatoitumaton IDH1-geeni kromosomin 10q puutoksen kanssa. Pyrosekvensointi 
osoittautui soveltuvan hyvin MGMT-geenin metyloitumisasteen määrittämiseen FFPE-
materiaalista. 
Osatöissä II ja III vertasimme kohdennettua uuden sukupolven sekvensointia fluoresenssi 
in situ hybridisaatioon, immunohistokemialliseen värjäykseen ja käänteistranskriptaasi-
PCR-menetelmään ALK-geenin fuusioiden tunnistamisessa (osatyö II), sekä PCR-
menetelmään EGFR-, KRAS-, ja BRAF-geenimutaatioiden tunnistamisessa (osatyö III). 
Tuloksemme osoittavat, että käytetyt menetelmät soveltuvat FFPE-näytteille ja eri 
menetelmillä saadut tulokset vastaavat hyvin toisiaan. Lisäksi kohdennettu uuden 
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sukupolven sekvensointi osoittautui hyödylliseksi tunnistettaessa uusia ja harvinaisia 
geenimuutoksia, joilla saattaa olla prediktiivistä arvoa. 
Osatyössä IV määritimme ALK-geenin fuusioiden esiintymisen suomalaisessa 
potilasaineistossa, joka koostui 469 ei-pienisoluista keuhkosyöpää sairastavasta 
potilaasta. Lisäksi tutkimme lähemmin ALK-geenin fuusiota kantavien potilaiden 
ominaisuuksia sekä fuusiogeenin esiintymistä 22 muun geenin mutaatioiden kanssa. 
Immunohistokemiallisen värjäyksen avulla määritimme ALK-geenin fuusioiden 
esiintyvän suhteellisen alhaisella frekvenssillä (2,3%) suomalaisissa 
keuhkosyöpäpotilaissa. ALK-positiiviset potilaat olivat merkittävästi nuorempia ja 
useammin täysin tupakoimattomia tai entisiä vähän tupakoivia. Vaikka suurin osa ALK-
positiivisista kasvaimista oli adenokarsinoomia, ALK-geenin fuusioita havaittiin myös 
suurisoluisissa karsinoomissa. Kohdennetun uuden sukupolven sekvensoinnin avulla 
havaittiin ALK-geenin fuusioita esiintyvän yhdessä geeneissä MET, TP53, CTNNB1, ja 
PIK3CA esiintyvien mutaatioiden kanssa, mutta lisätutkimuksia tarvitaan selvittämään 
näiden geenien yhteisesiintymisten merkitys.  
Tutkimuksemme osoittavat, että jotkin geneettiset ja epigeneettiset muutokset esiintyvät 
yhdessä. Näin ollen useita muutoksia samanaikaisesti tutkimalla voidaan saada 
kokonaisvaltaisempi kuva kasvaimen molekulaarisesta taustasta, mikä voi edesauttaa 
kasvaimen käytöksen, ennusteen ja hoitovasteen arvioimisessa. Lisäksi tuloksemme 
osoittavat pyrosekvensoinnin ja uuden sukupolven sekvensoinnin soveltuvuuden FFPE-
kasvainkudosnäytteille, sekä kohdennetun uuden sukupolven sekvensoinnin tuoman 
hyödyn geenifuusioiden ja -mutaatioiden tunnistamisessa muihin käytettyihin 
menetelmiin verrattuna, kuten mahdollisuuden selvittää samanaikaisesti useita 
geenimuutoksia. 
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INTRODUCTION 
 
Various genetic and epigenetic alterations contribute to cancer development, including 
numerical and structural chromosome aberrations, small DNA alterations, DNA 
methylation, histone modifications, and deregulated expression of small non-coding 
micro-RNAs (miRNAs). The presence of some of these genetic and epigenetic alterations 
may help to predict the response of the cancer patient to a specific treatment, thus serving 
as a predictive biomarker. Some alterations confer sensitivity to treatment, while others 
may be associated with resistance. An increasing number of therapeutic agents targeting 
specific cancer-related alterations are developed and investigated, the use of which may 
improve the survival of patients harboring the relevant alterations. 
Accurate screening for predictive biomarkers in routine molecular diagnostics is 
important to direct treatment to those who will likely benefit from it. Various different 
technologies exist for identification of different predictive biomarkers. Methylation-
specific pyrosequencing is one of the methods applicable for detection of methylation. It 
provides accurate quantitative information of the degree of methylation at individual CpG 
sites. The development of an increasing number of novel targeted treatments indicates the 
importance of applying methods for analysis of predictive biomarkers that enable the 
simultaneous identification of multiple alterations. Targeted next-generation sequencing 
(NGS) is a promising method for this purpose since it provides time- and cost-efficient 
assessment of numerous alterations. 
Gliomas are the most frequent malignant brain tumors arising from the supportive glial 
cells of the brain. Non-small cell lung cancer (NSCLC) is the most common type of lung 
cancer originating from epithelial cells of the lung. High-grade diffuse gliomas and 
advanced stage NSCLCs are associated with poor survival, which could be improved by 
the use of targeted molecular therapies. 
This thesis focuses on the analyses of predictive biomarkers in adult diffuse gliomas and 
NSCLCs. The use of pyrosequencing in the detection of gene promoter methylation, and 
targeted NGS in the detection of gene rearrangements and mutations is evaluated in 
formalin-fixed paraffin-embedded tumor tissue specimens.  
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REVIEW OF THE LITERATURE 
 
 Genetic and epigenetic alterations in cancer  
Cancer is a common complex disease arising from the malignant transformation and 
uncontrolled growth of a cell due to accumulation of genetic and epigenetic modifications 
affecting genome stability. Two to eight alterations are thought to suffice for development 
of the majority of cancers, with each alteration directly or indirectly increasing the growth 
advantage of the cell (Vogelstein et al., 2013). The two types of genes generally involved 
in tumor development are proto-oncogenes, which code for proteins participating in cell 
proliferation, division, or differentiation, and tumor suppressor genes, which code for 
proteins related to inhibition of cell proliferation. Also, DNA repair genes are considered 
to be tumor suppressor genes. Activating alterations in proto-oncogenes convert them into 
oncogenes, which promote cell proliferation, whereas inactivating alterations in tumor 
suppressor genes lead to loss of control of cell proliferation. During multistep 
tumorigenesis cancer cells are suggested to acquire the following hallmarks:  1) self-
sufficiency in growth signals, 2) insensitivity to antigrowth signals, 3) evasion of 
apoptosis, 4) unlimited replicative potential, 5) sustained angiogenesis, 6) tissue invasion 
and metastasis, 7) reprogramming of energy metabolism, and 8) evasion of immune 
destruction (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). The risk of 
developing a cancer depends not only on the individual´s genetic background, and 
inheritance of cancer-predisposing genetic variants, but also on the exposure to 
environmental and life-style factors such as tobacco smoking, alcohol, obesity, infectious 
agents (viruses, bacteria, parasites), environmental pollution, radiation, and carcinogens 
related to food and cooking (reviewed by Anand et al., 2008), which may induce genetic 
or epigenetic alterations. Interactions between genetic and environmental factors further 
contribute to cancer risk. 
 
1.1 Genetic alterations in cancer 
Various changes in the genome, including small sequence alterations, as well as larger 
structural and numerical chromosome aberrations are frequently seen in cancer, single-
base substitutions being the most prevalent alteration type in tumors (Vogelstein et al., 
2013). These changes may alter the normal function of the protein products of proto-
oncogenes and tumor suppressor genes, thus contributing to cancer development. The 
proteins encoded by oncogenes and their associated signaling pathways serve as targets 
for many therapeutic agents, including small-molecule inhibitors and monoclonal 
antibodies, which block oncogenic processes such as aberrant signaling (reviewed by 
Ciavarella et al., 2010). To date, many drugs designed to inhibit these targets have 
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received approval by the U.S. Food and Drug Administration (FDA) for treatment of 
various cancers (Abramson, 2014). 
 
1.1.1 Small DNA sequence alterations 
Small changes in DNA sequence, including substitutions, insertions, and deletions of one 
or a few nucleotides, affect the codon composition and may further alter the amino acid 
and protein structure (Figure 1). The substitutions of one base by another, known as 
single-nucleotide variants (SNVs) or point mutations, can lead to an alteration in the 
sequence that 1) does not change the amino acid, and thus, has no effect on the protein 
(silent mutation), 2) changes the amino acid, with potentially harmful consequences on 
the protein (missense mutation), or 3) causes an early stop codon, resulting in a shortened 
protein product (nonsense mutation). The changes affecting the amino acid sequence are 
also called non-synonymous alterations, whereas synonymous alterations have no effect 
on the amino acid sequence. Insertions and deletions of nucleotides can lead to alterations 
of the reading frame (frameshift mutation), and insertions can also affect the splicing of 
the introns (splice site mutation). When harmful sequence alterations occur in the coding 
regions of cancer-related genes, they may lead to activation of proto-oncogenes or 
inactivation of tumor suppressor genes. Point mutations and small deletions in the 
epidermal growth factor receptor (EGFR) gene, leading to its oncogenic activation, 
provide an example of small sequence alterations frequently detected in lung cancer (Pao 
et al., 2004). 
  
1.1.2 Structural and numerical chromosome alterations 
Structural chromosome alterations include deletions, duplications, inversions, 
substitutions, and translocations of chromosome arms or fragments of chromosomes 
(Figure 1). Deletions of chromosome parts lead to losses of genetic material, and 
duplications to gains of genetic material. Amplifications represent a higher increase in 
the number of copies of chromosome regions. Inclusion of proto-oncogenes in the 
duplicated or amplified chromosome regions may result in an overexpression of the 
encoded proteins, whereas deletion of chromosome regions containing tumor suppressor 
genes may cause a decrease in the expression of the encoded proteins. Translocations, 
inversions, and substitutions are rearrangements of DNA sequences between different 
chromosomes or within a single chromosome, which may result in a fusion of genes that 
are normally separated. The gene fusion could lead to a disruption of a gene at the 
breakpoint or generate a fused gene carrying a function that can promote tumorigenesis, 
especially when proto-oncogenes or tumor suppressor genes are involved at the 
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breakpoint. Structural chromosome alterations are classified as balanced when no genetic 
material is gained or lost, or unbalanced when gain or loss of genetic material is detected.  
Numerical chromosome alterations consist of gains and losses of whole chromosomes 
(aneuploidy). Although the actual role of aneuploid chromosomes in cancer is mostly 
unknown, it may be related to, for example, amplification of oncogenes, loss of tumor 
suppressor genes, or decrease in genome stability (reviewed by Gordon et al., 2012). 
Examples of chromosome alterations involved in cancer include deletion of chromosome 
10q and EGFR gene amplification in glioblastomas (Ohgaki et al., 2004), as well as an 
oncogenic activation of anaplastic lymphoma receptor tyrosine kinase (ALK) gene by its 
fusion with echinoderm microtubule-associated protein-like 4 (EML4) gene in NSCLC 
(Soda et al., 2007). 
                      
Figure 1. Common genetic alterations in cancer. A) Small DNA sequence alterations, including deletion, 
insertion, and substitution of one or a few base pairs. B) Structural chromosome alterations, including 
deletion, duplication, inversion, substitution, and translocation of chromosome regions. Image courtesy of 
National Human Genome Research Institute. 
 
1.2 Epigenetic alterations in cancer 
Epigenetic alterations, including DNA methylation, histone modifications, and 
deregulated expression of small non-coding miRNAs, are important contributors of 
 19 
 
tumorigenesis (Figure 2). These potentially reversible alterations affect gene expression 
without changing the DNA sequence.  
 
1.2.1 DNA methylation 
DNA methylation is an epigenetic event, in which a methyl group is added to cytosine of 
a CpG dinucleotide by enzymes known as DNA methyltransferases (DNMTs). Locally 
clustered CpG dinucleotides, called CpG islands, are predominantly found at the 5´end 
of many genes, and they are usually unmethylated in normal cells, although methylated 
promoter CpG islands are seen in some processes during normal development such as in 
genomic imprinting and X chromosome inactivation (reviewed by Bird, 2002). The 
majority of CpG sites located elsewhere in the genome, such as in the repetitive 
sequences, are generally highly methylated (Bird, 2002). The alterations in the 
methylation status of genes and genome have been frequently detected in tumors 
including, for example, the inactivation of tumor suppressor genes by hypermethylation 
of the CpG islands in their promoter regions, as well as hypomethylation of some 
normally methylated genomic regions, which might lead to genomic instability, 
reactivation of transposable elements, loss of imprinting, and activation of silent genes, 
thus contributing to tumorigenesis (reviewed by Esteller, 2008). An example of aberrant 
DNA methylation frequently found in specific types of cancer, such as gliomas, includes 
the hypermethylation of DNA repair gene O6-methylguanine-DNA methyltransferase 
(MGMT), leading to silencing of the gene (Esteller et al., 2000). 
Inhibitors of DNMTs, the increased expression of which is seen in many cancers, have 
been developed as drugs for cancer therapy (reviewed by Subramaniam et al., 2014). By 
inhibiting DNMTs, tumorigenicity could be reduced, as the expression of tumor 
suppressor genes is increased. To date, two DNMT inhibitors, azacytidine and decitabine, 
have obtained FDA approval for treatment of myelodysplastic syndromes (reviewed by 
Gnyszka et al., 2013). 
 
1.2.2 Histone modifications 
Histone proteins (H2A, H2B, H3, and H4, two copies of each), together with DNA 
wrapped around them, form the basic structure of chromatin, called the nucleosome. The 
protruding N-terminal tails of histones provide sites for posttranslational modifications, 
including acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, 
adenosine diphosphate ribosylation, deimination, and proline isomerization (reviewed by 
Kouzarides, 2007). Depending on the type of modifications and residues of the histone 
tails modified, the effects on chromatin structure, and further on gene transcription, DNA 
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repair, and DNA replication are different; some of them lead to loose, transcriptionally 
active euchromatin, whereas others lead to more condensed, transcriptionally inactive 
heterochromatin (Kouzarides 2007). Aberrations in histone modifications and histone-
modifying complexes are associated with cancer development (reviewed by Sawan and 
Herceg, 2010). For example, altered histone H4 modifications, including 
hyperacetylation of H4 K5 and H4 K8 and hypoacetylation of H4 K12 and H4 K16, have 
been identified in NSCLC cells (Van Den Broeck et al., 2008).  
Inhibitors for histone deacetylases (HDACs), the enzymes regulating gene expression by 
removing acetyl groups from histones, have been developed as anticancer agents 
(reviewed by West and Johnstone, 2014). The functions of HDAC inhibitors include 
induction of tumor cell apoptosis, growth arrest, senescence, differentiation, and 
immunogenicity, and inhibition of angiogenesis. To date, three HDAC inhibitors, 
vorinostat, romidepsin, and belinostat, have obtained FDA approval for treatment of 
cutaneous and peripheral T-cell lymphoma (Abramson, 2014). 
 
1.2.3 Small non-coding miRNAs 
MiRNAs are small non-coding RNAs, approximately 22 nucleotides in length, that bind 
sequence-specifically to messenger RNAs (mRNAs), and by mRNA degradation or 
inhibition of translation, miRNAs alter the gene expression of the target gene (reviewed 
by Bartel, 2004). MiRNAs are important in regulation of many processes in normal cells, 
including proliferation, apoptosis, and differentiation, but their altered expression (under- 
or overexpression) is associated with tumor development, and numerous deregulated 
miRNA expression patterns have been detected in various cancers (reviewed by 
Mirnezami et al., 2009). An example of involvement of miRNA in lung cancer is a 
reduced expression of let-7, with a possible role in increasing expression of the RAS 
oncogene (Takamizawa et al., 2004; Johnson et al., 2005). 
Small-molecule inhibitors of specific miRNAs, antisense oligonucleotides, locked 
nucleic acids, antagomirs, miRNA sponges, small interfering RNAs, and short hairpin 
RNAs are examples of treatment approaches for inhibition of oncogenic miRNAs, which 
are overexpressed in cancer and target tumor suppressor proteins (reviewed by Monroig 
et al., 2015). Small molecules affecting the RNA interference pathway provide an 
example of treatment strategies for recovery of tumor suppressor miRNAs, which are 
underexpressed in cancer and target oncogenes. To date, none of the studied agents has 
gained FDA approval as miRNA-targeting agents. Control of off-target effects and 
improved delivery are among the future challenges of miRNA therapies in cancer. 
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                                    Figure 2. Epigenetic alterations affecting gene expression. 
 
1.3 Predictive biomarkers for targeted therapies 
Some cancer-related genetic and epigenetic alterations driving tumorigenesis (“driver 
mutations”) are considered to be predictive biomarkers because their presence predicts 
the patients´ response to a specific therapy. Screening for predictive biomarkers enables 
tailoring of the cancer treatment based on the tumor´s genetic and epigenetic makeup; 
often expensive and possibly toxic therapies could specifically be prescribed for patients 
likely to benefit from the treatment. Conversely, treatment could be withheld from those 
patients unlikely to benefit or predicted to exhibit adverse side-effects. Some alterations 
may contribute to primary resistance to targeted therapy, and even those tumors with 
sensitizing alterations and a primary benefit from the therapy might sooner or later acquire 
resistance to it (reviewed by Garraway and Jänne, 2012). Examples of mechanisms 
leading to resistance include reactivation of the target due to secondary alterations and 
activation of upstream or downstream effectors or bypass oncoproteins of the signaling 
pathways involved in tumorigenesis. 
Currently, many molecular targeting drugs, including small-molecule compounds and 
monoclonal antibodies, have been approved for cancer treatment and many more are 
undergoing clinical and preclinical studies (Abramson, 2014). These agents act on 
specific molecules with alterations involved in tumorigenesis. While small-molecule 
compounds are able to pass through the cell membrane and target cytoplasmic molecules 
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and domains, monoclonal antibodies can target molecules outside the cell or on the cell 
surface (reviewed by Imai and Takaoka, 2006). As our understanding of cancer initiation, 
progression, and metastasis continues to broaden and novel candidates for targeted 
therapies are identified, the number of targeted drugs is expected to increase. 
Development of targeted therapies is important because they may improve the outcome 
of cancer patients. 
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 Gliomas 
2.1 Epidemiology 
Tumors in the brain and central nervous system were estimated to account for 1.8% 
(256 000) of new cancer cases and 2.1% (142 000) of cancer deaths worldwide in 2012 
(Ferlay et al., 2015). In Finland, tumors in the brain and central nervous system comprise 
2.6% of all cancers and 3.1% of total cancer deaths in males, while the corresponding 
figures in females are 4.0% and 3.6%, (NORDCAN, Association of Nordic Cancer 
Registries, 2013a). This thesis focuses on gliomas, which arise from the supportive glial 
cells of the brain and account for around 30% of all central nervous system and brain 
tumors and 80% of malignant brain tumors (Goodenberger and Jenkins, 2012). In addition 
to heritable risk variants, other factors with a proposed link to gliomas include, for 
example, ionizing radiation associated with increased risk and allergic conditions 
associated with reduced risk of gliomas (reviewed by Ostrom et al., 2014). Also, some 
monogenic Mendelian syndromes, such as neurofibromatosis 1, Li-Fraumeni syndrome, 
tuberous sclerosis, and Lynch syndrome, predispose to gliomagenesis, but only a small 
proportion of all glioma cases is explained by these syndromes. 
 
2.2 Histopathology and grading of gliomas 
Based on cellular morphology, the World Health Organization (WHO) classification 
divides gliomas into three major subtypes: astrocytomas, oligodendrogliomas, and a 
mixture of these two cell types, oligoastrocytomas (Louis et al., 2007a). Both 
oligondedrogliomas and oligoastrocytomas are also called oligodendroglial tumors. The 
histological WHO grading system provides information on the biological aspects of the 
tumors, aiding prognosis and prediction of treatment response. WHO grade I tumors are 
benign, discrete, and curable by surgical removal, whereas WHO grade II-IV diffuse 
gliomas infiltrate into the surrounding brain tissue, thus preventing complete surgical 
removal and cure (Claes et al., 2007; Louis et al., 2007a). Grade II tumors show increased 
cellularity, grade III tumors also show increased anaplasia and mitotic figures, and grade 
IV tumors show vascular proliferation and necrosis in addition to the aforementioned 
features (Louis et al., 2007a). Grade IV astrocytoma, glioblastoma, is the most frequently 
occurring and most malignant glioma subtype. It is further subdivided into primary 
glioblastomas (95% of cases), arising without evidence of pre-existing lower grade 
gliomas, and secondary glioblastomas (5% of cases), developing from lower grade 
gliomas (Ohgaki et al., 2004; Louis et al., 2007a). Primary and secondary glioblastomas 
can not be distinguished by histopathology, but they exhibit genetic and epigenetic 
differences, and patients with secondary glioblastomas are typically younger at diagnosis 
(Ohgaki and Kleihues, 2007). 
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Certain molecular alterations are frequently seen in specific glioma subtypes and grades, 
and thus, they may further aid in the classification of tumors. Examples of these 
alterations include codeletion of 1p/19q in oligodendroglial tumors (Reifenberger et al., 
1994; Bigner et al., 1999; Smith et al., 2000; Okamoto et al., 2004; Miller et al., 2006; 
Jeuken et al., 2011), IDH1 mutation in diffuse grade II-III gliomas and secondary 
glioblastomas (Balss et al., 2008; Hartmann et al., 2009; Watanabe et al., 2009; Yan et 
al., 2009), and loss of heterozygosity (LOH) of chromosome 10q, EGFR amplification, 
TP53 mutations, p16INK4a (CDKN2A) deletions, and PTEN mutations in glioblastomas 
(Ohgaki et al., 2004). In addition to contributing to the pathogenesis of gliomas, many of 
these molecular alterations have prognostic significance for prediction of outcome of 
patients (reviewed by Haynes et al., 2014). For example, codeletion of 1p/19q and IDH1 
mutations have been associated with favorable prognosis, whereas LOH 10q and PTEN 
mutations have been linked to poor prognosis.  
Many factors, such as WHO grade, tumor location, age of the patient, performance status, 
and presence of specific molecular alterations, contribute to the outcome and treatment 
response of glioma patients (Louis et al., 2007b). Population-based studies have shown 
the following 5-year survival rates (mean of the studies) for different glioma subtypes and 
grades: 68.5% in oligodendrogliomas (grade II), 50% in oligoastrocytomas, 41.9% in 
astrocytomas (grade II), 34.4% in anaplastic oligodendrogliomas (grade III), 19.8% in 
anaplastic astrocytomas (grade III), and 3.4% in glioblastomas (grade IV) (reviewed by 
Ostrom et al., 2014). Despite the relatively good survival from slowly growing low-grade 
gliomas, they eventually will progress to higher-grade gliomas (Riemenschneider et al., 
2010). 
 
2.3 Predictive biomarkers in adult diffuse gliomas 
2.3.1 Codeletion of chromosomes 1p and 19q 
Combined loss of whole chromosome arms 1p and 19q, potentially caused by an 
unbalanced translocation between the arms early in tumorigenesis (Reifenberger et al., 
1994; Jenkins et al., 2006), is a frequent change in oligodendroglial tumors, reported in 
44-89% of oligodendrogliomas (Reifenberger et al., 1994; Bigner et al., 1999; Smith et 
al., 2000; Okamoto et al., 2004; Miller et al., 2006; Jeuken et al., 2011) and in 19-38% of 
oligoastrocytomas (Bigner et al., 1999; Smith et al., 2000; Miller et al., 2006; Jeuken et 
al., 2011). In astrocytomas/glioblastomas, the codeletion of 1p/19q is a rare event (Smith 
et al., 2000; Miller et al., 2006; Jeuken et al., 2011). Although the tumor suppressor genes 
involved in the 1p/19q loss have not been unequivocally identified, some candidate genes 
have been discovered within the lost chromosome arms, including genes coding for 
capicua transcriptional repressor (CIC) located at 19q13.2 and far upstream element 
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(FUSE) binding protein 1 (FUBP1) located at 1p31.1 (Bettegowda et al., 2011). In 
patients diagnosed with anaplastic oligodendroglial tumors, the codeletion of 1p/19q has 
been associated with a better survival when the patients are treated with radiotherapy and 
combination chemotherapy of alkylating agents procarbazine and lomustine (CCNU) 
together with microtubule inhibitor vincristine (PCV) compared with radiotherapy alone 
(Cairncross et al., 2013; van den Bent et al., 2013). In a phase III trial, the median overall 
survival (OS) was 14.7 years for patients with codeleted anaplastic oligodendroglial 
tumors that were treated with PCV plus radiotherapy and 7.3 years for patients treated 
only with radiotherapy (hazard ratio (HR)=0.59; 95% confidence interval (CI) 0.37-0.95; 
p=0.03) (Cairncross et al., 2013). For patients lacking 1p/19q codeletion, the median 
survival was very similar regardless of the treatment received (2.6 vs 2.7 years; HR=0.85; 
95% CI 0.58-1.23; p=0.39). The predictive significance of codeleted 1p/19q has also been 
indicated in low-grade gliomas, which show a good response to temozolomide 
chemotherapy (Kaloshi et al., 2007). In addition to the predictive value of combined 
1p/19q loss, it also serves as a prognostic biomarker of a favorable prognosis (Aldape et 
al., 2007). 
 
2.3.2 MGMT promoter hypermethylation 
O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that 
functions in the removal of alkyl groups from O6 position of guanine caused by DNA-
alkylating agents such as temozolomide. Hypermethylation of the promoter region of the 
MGMT gene located at 10q26 leads to reduced MGMT expression and DNA repair 
activity, affecting the sensitivity of MGMT-methylated gliomas to alkylating agents 
(Esteller et al., 1999; Esteller et al., 2000). MGMT hypermethylation has been associated 
with an improved survival in glioblastomas treated with combined temozolomide and 
radiotherapy compared with radiotherapy alone (Hegi et al., 2005; Weller et al., 2009). 
In a study by Hegi et al. (2005), the median OS was 21.7 months (95% CI 17.4-20.4 
months) for MGMT-methylated glioblastoma patients treated with temozolomide plus 
radiotherapy compared with 15.3 months (95% CI 13.0-20.9 months) for patients treated 
with radiotherapy (p=0.007). For patients with unmethylated MGMT, the median OS was 
very similar regardless of the treatment received (12.7 months (11.6-14.4) vs. 11.8 
months (9.7-14.1)). Furthermore, among MGMT-methylated glioblastoma patients, the 
median progression-free survival (PFS) was 10.3 months (6.5-14.0) for temozolomide 
plus radiotherapy and 5.9 months (5.3-7.7) for radiotherapy alone (p=0.001), and among 
patients with unmethylated MGMT, 5.3 months (5.0-7.6) for temozolomide plus 
radiotherapy and 4.4 months (3.1-6.0) for radiotherapy alone (p=0.02). Recently, 
temozolomide treatment was compared with radiotherapy in elderly (>65-70 years) 
glioblastoma patients with and without MGMT hypermethylation (Malmstrom et al., 
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2012; Reifenberger et al., 2012; Wick et al., 2012). These studies suggested that MGMT 
hypermethylation predicts a favorable response to temozolomide treatment in elderly 
glioblastoma patients, whereas unmethylated MGMT seemed to predict lack of survival 
benefit from alkylating agent chemotherapy. For example, Wick et al. (2012) showed that 
the glioblastoma patients with MGMT hypermethylation had longer event-free survival 
when treated with temozolomide than patients treated with radiotherapy (8.4 months 
(95% CI 5.5-11.7) vs. 4.6 months (4.2-5.0)). On the other hand, the patients with 
unmethylated MGMT who received temozolomide showed shorter survival than those 
who underwent radiotherapy (3.3 months (3.0-3.5) vs. 4.6 months (3.7-6.3)). A resistance 
to temozolomide often emerges also in patients with hypermethylated MGMT promoter 
and a good primary response to temozolomide. Although the underlying mechanism for 
this resistance is not yet established, increased MGMT activity and DNA mismatch repair 
deficiency have been suggested (reviewed by Zhang et al., 2012). 
Hypermethylation of the MGMT promoter has been reported to occur in ~50% of 
astrocytomas (including glioblastomas) and in ~70% of oligodendroglial tumors 
(reviewed by Weller et al., 2010). Many studies have shown the value of MGMT 
hypermethylation in the prediction of favorable prognosis in various glioma subtypes 
(Esteller et al., 2000; Hegi et al., 2005; Everhard et al., 2006; van den Bent et al., 2009; 
Wick et al., 2009; Olson et al., 2011). The MGMT methylation status has also been 
suggested to be useful in distinguishing pseudoprogression from real progression of 
cancer, as MGMT hypermethylation is significantly associated with pseudoprogression 
(Brandes et al., 2008). Moreover, the presence of MGMT hypermethylation is 
significantly associated with IDH1 mutation and 1p/19q codeletion (Sanson et al., 2009; 
Hartmann et al., 2010, van den Bent et al., 2010; Mellai et al., 2011). Interestingly, a 
recent report showed that the assessment of both MGMT methylation and IDH1 mutation 
status in glioblastoma patients provides a better prediction of survival than either of the 
statuses alone (Molenaar et al., 2014). The longest survival was observed in patients 
carrying both MGMT methylation and IDH1 mutation, whereas patients with 
unmethylated MGMT and unmutated IDH1 had the shortest survival. Furthermore, IDH1 
mutation status is suggested to affect how MGMT-methylated high-grade gliomas benefit 
from alkylating agent chemotherapy, since MGMT hypermethylation is associated with a 
better survival in IDH1-negative but not IDH1-positive patients treated with 
chemotherapy (Wick et al., 2013). 
 
2.3.3 IDH1 mutations 
IDH1 gene located at chromosome 2q33.3 codes for cytocolic isocitrate dehydrogenase 
1 (NADP+) enzyme involved in the citric acid cycle. IDH1 mutations are early alterations 
in gliomagenesis, suggested to occur before TP53 mutations and codeletion of 1p/19q 
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(Watanabe et al., 2009). The mutations in IDH1 are detected in 64-100% of diffuse grade 
II-III gliomas, and secondary glioblastomas, but only in ~5-7% of primary glioblastomas 
(Balss et al., 2008; Hartmann et al., 2009; Watanabe et al., 2009, Yan et al., 2009). The 
majority of mutations in IDH1 affect the arginine amino acid at codon 132, which is 
substituted with histidine (R132H) in the most common type of mutations (Hartmann et 
al., 2009). Mutations in IDH2 gene (at 15q26.1) encoding the mitochondrial isocitrate 
dehydrogenase 2 (NADP+) enzyme are also observed in gliomas, but at a lower frequency 
(~3%) (Hartmann et al., 2009). IDH1 and IDH2 enzymes catalyze the conversion of 
isocitrate to α-ketoglutarate, but when mutated, they begin to produce the oncometabolite 
2-hydroxyglutarate, the accumulation of which is suggested to eventually lead to cancer-
promoting alterations such as genome-wide histone and DNA methylation changes (Dang 
et al., 2009; Noushmehr et al., 2010; Xu et al., 2011; Lu et al., 2012; Turcan et al., 2012). 
The predictive value of IDH1/2 mutations remains to be clarified; some studies have 
reported no impact of IDH1 mutations on response to temozolomide in low-grade 
astrocytomas (Dubbink et al., 2009) or PCV chemotherapy in anaplastic 
oligodendrogliomas (van den Bent et al., 2010), whereas others have shown an improved 
response to temozolomide chemotherapy in IDH-mutant low-grade gliomas (Houillier et 
al., 2010) and secondary glioblastomas (SongTao et al., 2012) or a benefit from PCV 
chemotherapy in anaplastic oligodendroglial tumors (Cairncross et al., 2014). Recently, 
promising results have been obtained by a selective R132H-IDH1 inhibitor, which 
appears to impair growth and promote differentiation of glioma cells harboring the IDH1 
mutation (Rohle et al., 2013). IDH-mutated gliomas have been associated with a favorable 
prognosis in numerous studies (Zou et al., 2013).  
 
2.3.4 Other potential therapeutic molecular targets in gliomas 
Several clinical studies of novel therapeutic agents targeting single or multiple molecular 
alterations of gliomas have been performed in recent years and many studies are ongoing 
(reviewed by Hamza and Gilbert, 2014). Examples of investigated therapeutic molecular 
targets include cell surface molecular receptors and their ligands, such as EGFR, VEGF, 
VEGFR, PDGFR, and integrins, downstream signaling effectors, such as Ras, MAPK 
(ERK), mTOR, and protein kinase C, and other molecular targets, such as histone 
deacetylases and proteasome. Many of these molecular targets show increased expression 
or activation in gliomas. Despite the large number of studies performed on potential 
therapeutic agents (e.g. inhibitors), none has shown significant improvement in the 
survival of glioma patients.  
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2.4 Treatment of gliomas 
The standard treatment options for newly diagnosed gliomas include surgical resection 
(or a biopsy if surgery cannot be performed), radiotherapy, and chemotherapy. Treatment 
for low-grade (grade II) diffuse gliomas consists of a resection, possibly followed by 
radiotherapy or chemotherapy (Soffietti et al., 2010; Tandon and Schiff, 2014). Options 
for treatment of anaplastic (grade III) gliomas include surgical resection, followed by 
radiotherapy and/or chemotherapy, whereas standard care for patients (<65-70 years) 
with glioblastomas (grade IV) combines resection, radiotherapy, and chemotherapy with 
the alkylating agent temozolomide (Stupp et al., 2005, Weller et al., 2014). Anaplastic 
oligodendroglial tumors harboring 1p/19q codeletion and elderly (>65-70 years) patients 
with glioblastomas harboring MGMT promoter hypermethylation can be treated by 
surgery and chemotherapy with or without radiotherapy (reviewed by Weller et al., 2014).  
The blood-brain barrier complicates the treatment of gliomas since many 
chemotherapeutic drugs cannot be delivered to the central nervous system across the 
barrier, and even with a successful delivery, the concentration of the drug in the brain 
might be low (Muldoon et al., 2007).   
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 Non-small cell lung cancer 
3.1 Epidemiology 
Globally, lung cancer is the most frequent type of cancer and the major cause of cancer-
related deaths in males and also ranks among the most common cancer types and cancer 
killers in females (Ferlay et al., 2015). An estimated 1.8 million new lung cancer cases 
(12.9% of all cancer cases) and 1.6 million deaths due to lung cancer (19.4% of all cancer 
deaths) occurred in 2012. In Finland, lung cancer accounts for 11.4% of all cancers and 
24.7% of total cancer deaths in males, whereas in females the corresponding proportions 
are 5.5% and 11.7% (NORDCAN, Association of Nordic Cancer Registries, 2013b). 
Tobacco smoking is the major risk factor for lung cancer (reviewed by Dela Cruz et al., 
2011). Examples of other factors known to increase the risk of developing lung cancer 
include genetic susceptibility, environmental tobacco smoke, and exposure to 
occupational lung carcinogens such as asbestos and radon. Non-small cell lung cancer 
(NSCLC), arising from epithelial cells of the lung, and small cell lung cancer (SCLC), 
arising from neuroendocrine cells of the lung, are the two main types of lung cancer. In 
this thesis, the focus is on the more prevalent type of lung cancer, NSCLC (~85% of all 
lung cancer cases). 
 
3.2 Histopathology and staging of NSCLC tumors 
Based on morphological features, the WHO 2004 classification divides NSCLC into three 
major histologic subtypes: adenocarcinoma, squamous cell carcinoma, and large cell 
carcinoma, the latter of which lacks clear differentiation (Travis et al., 2004). The use of 
immunohistochemical markers favoring a specific NSCLC subtype, such as 
adenocarcinoma-favoring thyroid transcription factor 1 (TTF-1) and squamous cell 
carcinoma-favoring p63, may help in the classification of poorly differentiated NSCLCs 
(reviewed by Travis et al., 2011). The location of adenocarcinomas and large cell 
carcinomas is usually the periphery of the lungs, whereas the majority of squamous cell 
carcinomas are centrally located (Travis et al., 2004). Adenocarcinoma is currently the 
most common NSCLC type (Ginsberg et al., 2007). Squamous cell carcinomas usually 
have the best prognosis, whereas large cell carcinomas are generally linked to poor 
prognosis (Ginsberg et al., 2007). Although all NSCLC subtypes are associated with 
smoking, the association is strongest with squamous cell carcinoma (Khuder, 2001). 
Different NSCLC subtypes carry genetic similarities, but some genetic alterations are 
more frequently seen in certain NSCLC subtypes, e.g. EGFR and KRAS mutations and 
ALK rearrangements in adenocarcinomas and FGFR1 amplification and DDR2 mutations 
in squamous cell carcinomas (reviewed by Cooper et al., 2013).  Histological 
classification of NSCLC tumors is important since it may help in the prediction of 
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efficacy and safety of treatment. For example, the use of the antifolate pemetrexed is 
associated with a treatment advantage in non-squamous cell carcinomas (Scagliotti et al., 
2009), while the anti-VEGF monoclonal antibody bevacizumab is linked to bleeding risk 
in patients with squamous cell carcinoma (Johnson et al., 2004). 
NSCLC tumors are staged according to the tumor, node, metastasis (TNM) classification 
system in which the size of the primary tumor (T), spread to regional lymph nodes (N), 
and metastasis to distant sites (M) are defined (reviewed by Detterbeck et al., 2009). 
Based on TNM classification, the tumors can be further divided into stage groups Ia, Ib, 
IIa, IIb, IIIa, IIIb, and IV. The prognosis of NSCLC depends greatly on the stage of the 
disease, and because lung cancer is mostly diagnosed at an advanced stage, the prognosis 
is poor. The overall 5-year survival rate of NSCLC is 18.2%, whereas the rates are 53.5% 
for local lung cancer, 26.1% for regional lung cancer, and only 3.9% for metastasized 
lung cancer (DeSantis et al., 2014).  
 
3.3 Predictive biomarkers in non-small cell lung cancer 
3.3.1 EGFR mutations 
Epidermal growth factor receptor (EGFR), encoded by the EGFR gene at chromosome 
7p12, is a cell-surface tyrosine kinase receptor that affects various cellular processes, such 
as proliferation, differentiation, and inhibition of apoptosis, by regulating downstream 
signal transduction pathways. Mutations in EGFR are usually found in exons 18-21, 
within the intracellular tyrosine kinase domain (reviewed by Sharma et al., 2007). The 
most frequent EGFR mutations include exon 19 deletions and a leucine-to-arginine 
substitution at codon 858 (L858R), together comprising around 90% of all EGFR 
mutations (Ladanyi and Pao, 2008). The frequency of EGFR mutations varies by 
ethnicity, histology, smoking history, and sex, occurring more commonly in Asian 
(29.1%) than non-Asian (7.9%) populations, in adenocarcinomas (31.3%) than in other 
NSCLC subtypes (2.3%), in never-smokers (50.8%) than in smokers (9.0%), and in 
females (37.5%) than in males (13.0%) (reviewed by Pao and Miller, 2005). In Finnish 
NSCLC patients, the prevalence of EGFR mutations is reported to be 11.4% (Mäki-
Nevala et al., 2014). Although occasional coexistence occurs, EGFR mutations are 
usually mutually exclusive with mutations in genes such as ALK, KRAS, and BRAF 
(Dearden et al., 2013). 
Mutated EGFR leads to hyperactivation of downstream signaling pathways, including the 
Ras–Raf–MEK–MAPK (ERK) and PI3K–Akt pathways, and further promotion of pro-
survival and anti-apoptotic signals, thus inducing tumorigenesis (reviewed by Sharma et 
al., 2007). EGFR mutations usually occur around the adenosine triphosphate (ATP)-
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binding site within the tyrosine kinase domain of EGFR, targeted also by EGFR tyrosine 
kinase inhibitors (TKIs), which compete with ATP for binding to the active site of 
tyrosine kinase domain, thus inhibiting autophosphorylation and downstream signaling 
(Sharma et al., 2007). Patients with advanced NSCLC harboring sensitizing EGFR-
activating mutations, such as exon 19 deletions and point mutation L858R (Figure 3), 
have shown a great benefit and improved PFS over platinum-doublet chemotherapy when 
treated with the first-generation reversible EGFR TKIs, gefitinib and erlotinib, as well as 
with the second-generation irreversible EGFR inhibitor, afatinib, which attaches to the 
kinase domain by forming irreversible covalent bonds (Mok et al., 2009; Maemondo 
2010; Mitsudomi et al., 2010; Zhou et al., 2011; Rosell et al., 2012; Sequist et al., 2013). 
In randomized phase III trials among EGFR-mutated patients, median PFS was 9.5 
months for gefitinib compared with 6.3 months for carboplatin plus paclitaxel (HR=0.48; 
95% CI 0.36–0.64; p<0.001) (Mok et al., 2009), 13.1 months for erlotinib compared with 
4.6 months for gemcitabine plus carboplatin (HR=0.16, 95% CI 0.10–0.26; p<0.0001) 
(Zhou et al., 2011), and 11.1 months for afatinib compared with 6.9 months for cisplatin 
plus pemetrexed (HR=0.58; 95% CI 0.43-0.78; p=0.001) (Sequist et al., 2013) when 
EGFR TKIs were used as first-line treatment. Mok et al. (2009) also showed that EGFR-
negative NSCLC patients who received carboplatin plus paclitaxel had significantly 
longer median PFS than those treated with gefitinib (HR=2.85; 95% CI 2.05-3.98; 
p<0.001). In contrast to PFS, the above-mentioned EGFR TKIs do not seem to provide 
significant OS benefit over chemotherapy. However, the OS data presented in some of 
the studies was only preliminary, comprising a small part of the study populations (Mok 
et al., 2009; Maemondo et al., 2010; Rosell et al., 2012; Sequist et al., 2013). 
A randomized phase III trial of another EGFR TKI, icotinib, showed no significant 
difference in PFS between icotinib and gefitinib in pretreated patients with advanced 
NSCLC; median PFS was 4.6 months for icotinib and 3.4 months for gefitinib (HR=0.84; 
95% CI 0.67-1.05; p=0.13)  (Shi et al., 2013). Among EGFR-mutated patients, median 
PFS was 7.8 months for icotinib and 5.3 months for gefitinib (HR=0.78; 95% CI 0.42–
1.28, p=0.32). Similarly, no significant difference in median OS was seen between the 
treatment groups. 
 
3.3.1.1. Resistance to EGFR tyrosine kinase inhibitor therapy 
Some EGFR mutations, including a threonine-to-methionine substitution at codon 790 
(T790M) and exon 20 insertion mutations (Figure 3) (Inukai et al., 2006; Wu et al., 2008; 
De Pas et al., 2011; Wu et al., 2011; Lund-Iversen et al., 2012; Yasuda et al., 2012), as 
well as a deletion polymorphism of the gene coding for pro-apoptotic BCL2-like 11 
(BIM) (Ng et al., 2012) have been linked to primary TKI resistance. Furthermore, even 
patients exhibiting initial response to EGFR TKIs eventually develop a drug resistance. 
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EGFR T790M mutation serves as a common mechanism of acquired resistance and is 
detected in ~50% of the resistant cases (Kobayashi et al., 2005; Pao et al., 2005). Other 
mechanisms associated with acquired resistance to EGFR TKIs include histologic 
transformation of NSCLC to SCLC and activation of alternative signaling pathways via 
various gene alterations such as MET amplifications and BRAF mutations, among others 
(reviewed by Chong and Jänne, 2013; Ohashi et al., 2013). To overcome acquired 
resistance, novel EGFR TKIs and multi-targeted drugs are under investigation. Among 
these are the promising irreversible third-generation pyrimidine EGFR TKIs selectively 
targeting the sensitizing mutations and the resistant EGFR T790M mutation (Zhou et al., 
2009; Walter et al., 2013; Cross et al., 2014). 
 
Figure 3. Common mutations in exons 18-21 of EGFR gene tyrosine kinase domain associated with 
drug sensitivity and resistance. Figure adapted from Sharma et al. (2007). 
 
3.3.2 ALK fusions 
The anaplastic lymphoma tyrosine kinase (ALK) gene, located at chromosome 2p23, 
encodes a transmembrane tyrosine kinase receptor, which participates in the activation of 
downstream signaling pathways and further regulates cell proliferation, differentiation, 
and apoptosis. The most commonly detected ALK translocation is its fusion with EML4 
gene (at 2p21) by a small inversion in chromosome arm 2p (Soda et al., 2007). In all of 
the identified EML4-ALK fusion variants, the fusion starts at exon 20 of ALK, including 
its tyrosine kinase domain, but EML4 is truncated at various points (Horn and Pao, 2009). 
The most frequently detected EML4-ALK variants among NSCLC patients are variant 1, 
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in which exon 20 of ALK is fused to exon 13 of EML4 (33%), and variant 3a/3b, in which 
exon 20 of ALK is fused to exon 6a/b of EML4 (29%) (reviewed by Sasaki et al., 2010). 
Other more rarely observed fusion partners of ALK include KIF5B, TFG, and KLC1 
(Rikova et al., 2007; Takeuchi et al., 2009; Togashi et al., 2012). ALK fusions occur in 
~3% of unselected NSCLC patients (reviewed by Bang, 2011), more frequently in 
patients with adenocarcinoma histology, younger age, never- or light smoking history, 
and lack of other driver gene mutations (Inamura et al., 2009; Rodig et al., 2009, Shaw et 
al., 2009; Wong et al., 2009; Takahashi et al., 2010; Sequist et al., 2011).  
ALK fusions lead to constitutive dimerization and activation of the fusion oncogene and 
further to activation of various signaling pathways, such as the Ras–ERK, JAK3–STAT3, 
and PI3K–Akt pathways, and eventually enhancement of cell proliferation and survival 
(Soda et al., 2007; Chiarle et al., 2008; Soda et al., 2008). The ALK TKI crizotinib has 
shown a great efficacy in the treatment of NSCLC patients harboring ALK fusions and a 
superiority to standard chemotherapy (Kwak et al., 2010; Camidge et al., 2012; Shaw et 
al., 2013). In a randomized phase III trial, Shaw et al. (2013) showed that crizotinib 
significantly improved median PFS over pemetrexed or docetaxel chemotherapy (7.7 
months vs 3.0 months; HR=0.49; 95% CI 0.37-0.64; p<0.001) in ALK-positive patients 
with locally advanced or metastatic NSCLC. No significant difference in OS was 
observed between patients treated with crizotinib and chemotherapy. Despite sensitivity 
to the ALK TKI, ALK-positive patients are suggested not to benefit from EGFR TKIs 
(Shaw et al., 2009).  
 
3.3.2.1. Resistance to ALK tyrosine kinase inhibitor therapy 
Despite the good response to crizotinib, even ALK-positive tumors eventually develop 
acquired resistance. Although the mechanisms of this resistance remain unknown in some 
of the patients, speculated mechanisms include secondary ALK mutations, ALK 
amplification and copy number gain, KRAS mutations, and activation of HER family 
signaling such as EGFR signaling (Sasaki et al., 2011; Tanizaki et al., 2012; Doebele et 
al., 2012; Katayama et al., 2012). To overcome such resistances, novel next-generation 
ALK TKIs, such as multi-targeted ceritinib, and heat-shock protein 90 (Hsp90) inhibitors 
have been developed, towards which ALK-positive patients have shown clinical response 
(Sequist et al., 2010; Seto et al., 2013; Socinski et al., 2013; Shaw et al., 2014). 
 
3.3.3 Other potential therapeutic molecular targets in NSCLC 
Novel single-target and multi-target therapies for NSCLC are under active investigation; 
some of these have shown promising results in preclinical and/or clinical studies 
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(reviewed by Gerber et al., 2014). Examples of potential target molecular alterations for 
these drugs include alterations in receptor tyrosine kinases DDR2, FGFR, HER2, MET, 
NTRK1, RET, and ROS1 as well as mutations in downstream signaling mediators AKT, 
BRAF, MEK1, KRAS, NRAS, and PIK3CA (Table 1). 
 
3.4 Treatment of NSCLC 
Standard treatment choices for NSCLC comprise surgery, radiotherapy, and 
chemotherapy. The most common treatment for early, localized stage NSCLCs is surgery, 
whereas advanced stage NSCLCs are most frequently treated with combined radiotherapy 
and chemotherapy (DeSantis et al., 2014). The development of small-molecule TKIs, 
targeting specific genetic alterations within cancer cells, has greatly improved the survival 
of patients carrying these alterations. Currently, FDA-approved targeted drugs for 
advanced NSCLC include gefitinib (Cohen et al., 2004), erlotinib (Khozin et al., 2014), 
and afatinib (Dungo and Keating, 2013) for treatment of patients harboring EGFR 
mutations, and crizotinib (Malik et al., 2014) and ceritinib (Cooper et al., 2015) for 
treatment of patients harboring ALK rearrangements. Furthermore, the China Food and 
Drug Administration has approved the EGFR TKI icotinib for treatment of EGFR-
positive NSCLC patients (Hu et al., 2014). 
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 Methods in the analysis of predictive biomarkers in diffuse gliomas 
and non-small cell lung cancer 
The predictive biomarkers of diffuse gliomas and NSCLC could be screened using a 
variety of methods. Here, the focus is on methods applicable for the detection of MGMT 
promoter hypermethylation, ALK fusions, and EGFR mutations. The methods with most 
relevance in this thesis, i.e. methylation-specific pyrosequencing and targeted NGS, will 
be described in more detail. 
 
4.1 Testing of MGMT gene promoter hypermethylation in diffuse gliomas 
The 5´CpG island of the MGMT gene, which covers partly the promoter region and exon 
1, consists of 98 CpG sites. It is currently not fully clear which and how many of the 
CpGs should be methylated to result in MGMT silencing, and which testing method is 
optimal for determining MGMT promoter methylation status (Wick et al., 2014). Each of 
the available MGMT testing methods analyzes partly different CpG sites (Weller et al., 
2010). Examples of the methods applicable for detection of MGMT promoter 
hypermethylation include methylation-specific PCR (MSP) (Herman et al., 1996; Esteller 
et al., 1999; Esteller et al., 2000), quantitative MSP (Vlassenbroeck et al., 2008), 
methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) 
(Jeuken et al., 2007), pyrosequencing (Mikeska et al., 2007), quantitative real-time PCR 
MethyLight (Eads et al., 2000), methylation-sensitive high-resolution melting (MS-
HRM) (Wojdacz and Dobrovic, 2007), and combined bisulfite restriction analysis 
(COBRA) (Xiong and Laird, 1997). Among these methods, MSP is the only qualitative 
method, others being quantitative or semiquantitative. All of the above-mentioned 
methods, except MS-MLPA, consist of bisulfite treatment of DNA, in which 
unmethylated cytosines are converted to uracils and further to thymines, whereas 
methylated cytosines remains unchanged. In addition to methods identifying the MGMT 
promoter methylation, MGMT protein expression by immunohistochemistry (IHC) 
(Capper et al., 2008), mRNA expression by real-time quantitative reverse-transcription 
PCR (RT-PCR) (Tanaka et al., 2003), and enzymatic MGMT activity (Preuss et al., 1995) 
could be assessed, although these analyses are susceptible to contamination by non-
neoplastic cells expressing MGMT. Affordability and simplicity likely make qualitative 
gel-based MSP the most frequently used MGMT analysis method; in this method, 
methylation-specific primers are designed to distinguish between methylated and 
unmethylated sequences (Herman et al., 1996; Esteller et al., 1999; Esteller et al., 2000). 
However, in the case of low-quality DNA derived from, for instance, formalin-fixed 
paraffin-embedded (FFPE) tissue specimens, MSP is prone to false-positive and false-
negative results (Mikeska et al., 2007). 
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4.1.1 Pyrosequencing as a method for MGMT promoter methylation testing 
Pyrosequencing is a sequencing-by-synthesis method in which nucleotide incorporation 
to single-stranded DNA by polymerase leads to the release of a pyrophosphate (PPi) 
(Ronaghi, 2001) (Figure 4). Catalyzed by ATP sulfurylase, PPi is converted to ATP, 
which is used by luciferase to oxidize luciferin and produce light proportional to the 
number of incorporated nucleotides. The fourth enzyme involved in the process is the 
nucleotide-degrading enzyme apyrase. In methylation-specific pyrosequencing, each 
studied CpG site obtains a value between 0 and 100%, providing accurate information on 
the extent of methylation at individual CpGs (Mikeska et al., 2007). Thus, 
pyrosequencing enables also the detection of low methylation and a heterogeneous 
methylation pattern. Pyrosequencing has proven to be a robust and sensitive method in 
the detection of MGMT hypermethylation in gliomas, also from FFPE tissue material 
(Mikeska et al., 2007; Dunn et al., 2009; Karayan-Tapon et al., 2010; Havik et al., 2012; 
Quillien et al., 2012). Furthermore, pyrosequencing appears to be the best predictor of 
clinical outcome of glioma patients in comparison with other methods, including MSP, 
semiquantitative MSP, real-time quantitative MSP, MethyLight, MS-HRM, quantitative 
RT-PCR, and IHC (Karayan-Tapon et al., 2010; Havik et al., 2012; Quillien et al., 2012). 
Limitations of pyrosequencing are the requirement of expensive equipment and a high 
cost per sample, when only a few samples are analyzed per run. Thus, pyrosequencing 
serves better in high-throughput analyses. Also, a major drawback of pyrosequencing is 
the lack of a clear cut-off value distinguishing between methylated and unmethylated 
cases. Recently, however, Quillien et al. (2014) validated a cut-off of 9% for the 
commonly and successfully used commercial PyroMark CpG MGMT kit applicable for 
assessment of methylation at five CpG sites (used also in the Study I of this thesis). 
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Figure 4. Principles of pyrosequencing. Figure reprinted by permission from Macmillan Publishers Ltd: 
[Nature Reviews Neurology]. Wick et al., 2014, copyright 2014. 
 
4.2 Detection of ALK fusions and EGFR mutations in NSCLC 
Currently, screening for ALK fusions and EGFR mutations is recommended for all 
NSCLC patients with advanced-stage adenocarcinoma, regardless of other clinical factors 
(Lindeman et al., 2013). ALK fusions could be identified using various different methods, 
including fluorescence in situ hybridization (FISH) (Kwak et al., 2010; Camidge et al., 
2010), IHC with anti-ALK antibodies, such as 5A4 (Paik et al., 2011a) and D5F3 (Mino-
Kenudson et al., 2010), RT-PCR based methods (Takeuchi et al., 2008; Sanders et al., 
2011; Soda et al., 2012; Wang et al., 2012; Li et al., 2014b), chromogenic in situ 
hybridization (CISH) (Yoshida et al., 2011b), exon-array profiling (Lin et al., 2009), and 
NGS (Peled et al., 2012). At the moment, FISH using the Vysis ALK Break Apart FISH 
Probe Kit (Abbott Molecular Inc., Des Plaines, IL, USA) is the standard, FDA-approved 
companion diagnostic test for screening ALK-positive patients eligible for crizotinib 
treatment (U.S. Food and Drug Administration, 2014). FISH is clinically validated, 
applicable on FFPE tissues, requires only a small amount of tumor tissue, and identifies 
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various ALK rearrangements (Weickhardt et al., 2013). However, FISH is relatively 
expensive, the interpretation of FISH results might be challenging, the fusion partner or 
variants may not be specified, and rare, complex rearrangements might go unrecognized.  
For EGFR mutation screening, several different methods could be applied (reviewed by 
Ellison et al., 2013). Examples of these methods include Sanger sequencing (direct 
sequencing), denaturing high-performance liquid chromatography (dHPLC) (Cohen et 
al., 2006), high-resolution melting analysis (HRMA) (Takano et al., 2007), NGS 
(Querings et al., 2011), pyrosequencing (Dufort et al., 2011), Smart Amplification 
Process (SmartAMP) (Hoshi et al., 2007), IHC using EGFR mutation-specific antibodies 
(Yu et al., 2009; Brevet et al., 2010), TaqMan PCR (Endo et al., 2005), Amplification 
Refractory Mutation System (ARMS) (Ellison et al., 2010), and fragment length analysis 
(Pan et al., 2005). The standard method for the assessment of EGFR mutation status has 
long been Sanger sequencing, which, although being accurate, is also costly, time-
consuming, and suffers from rather low sensitivity. Recently, the FDA has approved two 
real-time PCR-based companion diagnostic tests for selection of EGFR-mutated patients 
for specific targeted drugs: the cobas EGFR Mutation Test (Roche Molecular Systems 
Inc, Pleasanton, CA, USA) for erlotinib and the real-time PCR-based therascreen EGFR 
RGQ PCR Kit (Qiagen Ltd., Manchester, UK) for afatinib (U.S. Food and Drug 
Administration, 2014). 
 
4.2.1 Targeted next-generation sequencing as a method for detection of genetic 
alterations 
NGS enables the parallel sequencing of a large number of sequences in a single run, with 
a lower cost and a higher sensitivity than the traditionally used Sanger sequencing (Tran 
et al., 2012). NGS methods have developed rapidly in recent years and currently various 
technologies are available, each of them combining a different set of sample preparation, 
sequencing, and data analysis (Metzker, 2010; Tran et al., 2012). In this thesis, Illumina 
HiSeq2000 (Illumina, San Diego, CA, USA) and Ion Torrent Personal Genome Machine 
(PGM, Life Technologies, Carlsbad, CA, USA) platforms were used. Illumina 
sequencing technology utilizes a sequencing-by-synthesis approach and reversible 
terminator chemistry (Bentley et al., 2008), whereas Ion Torrent semiconductor 
sequencing is a non-optical NGS method based on hydrogen ion (pH change) detection 
(Rothberg et al., 2011) (Figure 5). 
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                            Figure 5. An overview of next-generation sequencing on Illumina 
                            HiSeq2000 and Ion Torrent PGM platforms. 
 
Especially beneficial for diagnostic purposes is the targeted NGS strategy, in which only 
the regions of interest, such as the clinically relevant genes, are enriched and sequenced. 
This permits higher coverage as well as reduced cost per sample compared with whole–
genome sequencing (Robison, 2010). The most commonly applied methods for target 
enrichment of desired genomic regions include PCR-amplicon and on-array or in-solution 
hybridization capture (Mamanova et al., 2010). Compared with the majority of 
traditionally used methods in mutation screening that enable the detection of one or a few 
mutations in a gene at a time, NGS offers the possibility for parallel detection of various 
types of alterations in a single run, eliminating the need for sequential single-gene testing. 
Thus, as the number of predictive biomarkers in lung cancer, and also in other cancers, 
rises, all of them could be analyzed simultaneously. NGS also enables the detection of 
low frequency alterations, even in specimens with a low tumor percentage. ALK 
rearrangements, EGFR, and also other mutations have been successfully detected using 
various NGS platforms, also on FFPE, cytology specimens, and fine needle aspirates 
(Quering et al., 2011; Peled et al., 2012; Singh et al., 2013; Spencer et al., 2013; Abel et 
al., 2014; Chevrier et al., 2014; Han et al., 2014; Karnes et al., 2014; Lin et al., 2014; 
Gailey et al., 2015). NGS has enabled more accurate detection of genetic alterations than 
some traditionally used methods, including FISH and Sanger sequencing (Querings et al., 
2011; Peled et al., 2012; Abel et al., 2014; Chevrier et al., 2014; Han et al., 2014). The 
data analysis and interpretation of NGS results might, however, be challenging, requiring 
expertise in the field.  
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AIMS OF THE STUDY 
 
At the beginning of this decade, personalized treatments in diffuse gliomas and NSCLC 
required the assessment of predictive biomarkers. In order to tailor treatments also in 
Finland, there was a need to set up modern biomarker analytics, to evaluate the feasibility 
of FFPE tumor tissue material for the diagnostic biomarker analyses, and to identify the 
special features of Finnish patients. The overall aim of this study was to analyze predictive 
biomarkers in Finnish patients with diffuse gliomas and NSCLC using various methods. 
Specific aims were as follows: 
• to analyze MGMT gene promoter hypermethylation, chromosomal copy number 
aberrations, IDH1 mutation, and associations between these in diffuse gliomas 
(I) 
• to evaluate the use of pyrosequencing in the detection of MGMT 
hypermethylation in FFPE glioma specimens  (I) 
• to determine the suitability of targeted NGS in the detection of ALK fusion and 
EGFR, KRAS, and BRAF mutations in NSCLC FFPE tumor tissue specimens by 
comparing the NGS results with the results obtained from the commonly used 
methods of FISH, IHC, real-time RT-PCR, and real-time PCR (II, III) 
• to identify potential novel mutations in EGFR, KRAS, and BRAF genes in 
NSCLC by NGS (III) 
• to determine the frequency of ALK fusion in Finnish NSCLC patients and its 
association with clinicopathological characteristics and with 22 other driver gene 
mutations (IV). 
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MATERIALS AND METHODS 
 
This section describes the main features of the samples and methods used in this study. 
More detailed descriptions can be found in the original publications. Table 2 provides an 
overview of the samples and methods used in Studies I-IV. 
 
 Study samples 
5.1 Glioma patient samples (I) 
Study I comprised 51 adult diffuse glioma patients diagnosed and operated on at the 
University Hospitals of Helsinki and Oulu, Finland, between 2008 and 2010. According 
to the WHO 2007 classification, 18 (35.3%) of the patients were diagnosed with 
oligoastrocytoma (grade II-III), 15 (29.4%) with oligodendroglioma (grade II-III), 15 
(29.4%) with glioblastoma (grade IV), and 3 (5.9%) with astrocytoma (grade II-III). 
Forty-five of the tumor tissue specimens were formalin-fixed and paraffin-embedded, 
whereas six were frozen. The content of neoplastic cells within tumor specimens was 
microscopically confirmed to be >50%. Detailed information on the clinical 
characteristics of the patients is presented in original publication I. 
 
5.2 Non-small cell lung cancer patient samples (II, III, IV) 
For Studies II, III, and IV, we collected FFPE tumor tissue specimens from NSCLC 
patients diagnosed and treated at the Helsinki and Uusimaa Hospital District, Finland, 
between 2005 and 2012. The histopathological diagnosis and the tumor tissue content of 
all specimens were reviewed by a pathologist. The patients selected for Studies II and III 
were predominantly non-smokers with adenocarcinoma histology. Study II included 87 
patients, 92.0% of whom were adenocarcinomas, and Study III included 81 patients, 
91.4% of whom were adenocarcinomas. Study IV comprised 469 NSCLC patients, 
including 363 adenocarcinomas (77.4%), 57 squamous cell carcinomas (12.1%), 35 large 
cell carcinomas (7.5%), and 14 other subtypes or not otherwise specified NSCLCs 
(3.0%). Of these patients, 54 (11.6%) were never-smokers, 44 (9.5%) ex-light smokers, 
155 (33.3%) ex-medium smokers, and 212 (45.6%) current smokers. Smoking status was 
not available for four patients. Detailed information on the clinical characteristics of the 
patients is presented in original publications II, III, and IV. 
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Table 2. Overview of the patient samples and methods used in Studies I-IV.  
 Study I Study II Study III Study IV 
Tumor type Glioma NSCLC NSCLC NSCLC 
Number of patients 51 87 81 469 
Female/male ratio 25/26 42/45 44/37 221/248 
Mean*/median** 
age (range) 
41.2* (19-63) 63.7* (44-82) 64.0* (44-86) 65.0** (32-85) 
Methods 
 
Array CGH, IHC, 
pyrosequencing 
FISH, IHC, 
targeted NGS, 
real-time RT-
PCR 
Targeted NGS, 
real-time PCR 
FISH, IHC, 
targeted NGS 
Sample material FFPE, frozen FFPE FFPE FFPE, fine needle 
aspirations, core 
needle biopsies 
Array CGH, array comparative genomic hybridization; FFPE, formalin-fixed paraffin-embedded; FISH, 
fluorescence in situ hybridization; IHC, immunohistochemistry; NGS, next-generation sequencing; 
NSCLC, non-small cell lung cancer; RT-PCR, reverse transcription-polymerase chain reaction 
 
 Analysis methods 
6.1 Nucleic acid extraction (I, II, III, IV) 
In Studies I, II, III, and IV, QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) 
was used for extraction of DNA from FFPE tumor tissue sections according to the 
manufacturer´s recommendations with minor modifications. For Study 1, the 
concentration and purity of DNA were measured by Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE, USA), and for 
Studies II, III, and IV by Qubit® fluorometer (Life Technologies, Carslbad, CA, USA). 
In Study II, RNeasy FFPE Kit (Qiagen) was used for extraction of RNA from FFPE tumor 
tissue sections (16 µm) according to the manufacturer´s instructions. The RNA quantity 
was assessed using Qubit® fluorometer (Life Technologies). 
 
6.2 Pyrosequencing (I) 
In Study I, MGMT gene hypermethylation in 51 gliomas was analyzed using 
pyrosequencing technology. Bisulfite conversion of the extracted DNA (500-1000 ng) 
with EpiTect Bisulfite Kit (Qiagen) and subsequent PCR amplification of the bisulfite-
converted DNA (50-100 ng in 25 or 50 µl reactions) with PyroMark PCR Kit (Qiagen) 
were performed according to the manufacturer´s instructions. The PCR products were 
checked using 2.2% DNA cassette on a FlashGel® System (Lonza Group Ltd., Basel, 
Switzerland). For detection of methylation in five CpG sites in exon 1 of the MGMT gene, 
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PyroMark MGMT Kit (Qiagen) on a PSQ96MA system (Biotage AB, Uppsala, Sweden) 
was used following the manufacturers´ protocols. The analysis was controlled using an 
internal control for confirmation of bisulfite conversion, a few replicate samples for 
controlling intratumoral variability, and commercial methylated and unmethylated human 
DNA samples (Qiagen) serving as positive and negative controls for methylation. Pyro 
Q-CpG software™ (Biotage AB) was used for data analysis. Based on a report by Dunn 
et al., (2009), a threshold of 9% (the average methylation over the five CpG sites studied) 
was selected for hypermethylation; tumors with an average methylation of <9% were 
classified as unmethylated, whereas an average methylation of 9-29% was considered low 
methylation and an average methylation of >29% high methylation.  
 
6.3 Array comparative genomic hybridization (I) 
Array comparative genomic hybridization (array CGH) analysis was performed to detect 
chromosomal copy number aberrations in 42 gliomas using 44K or 244K oligonucleotide 
microarrays (Agilent Technologies, Santa Clara, CA, USA). All protocol steps, including 
digestion, labeling, and hybridization of the DNA samples, as well as washing and 
scanning of the microarray slides with Agilent´s microarray scanner, were done following 
the manufacturer´s instructions, as described elsewhere (Koski et al., 2009). The data 
were extracted from microarray images with Agilent´s Feature Extraction software and 
analyzed with CGH Analytics software (Agilent Technologies). For visualization of the 
array CGH results, the Progenetix software analysis tool (Baudis and Cleary, 2001) was 
used.  
 
6.4 Immunohistochemistry (I, II, IV) 
In Study I, IHC was performed using an antibody for IDH1 R132H (clone H09, Dianova, 
Hamburg, Germany), diluted 1:40, for identification of the IDH1 mutation R132H in 51 
glioma tumor tissue sections (4 µm). The section slides were stained using BenchMark 
XT automated slide staining system (Ventana Medical Systems, Inc., Tucson, AZ, USA) 
and ultraView Universal DAB Detection Kit (Ventana Medical Systems, Inc.). In Studies 
II and IV, a mouse monoclonal primary antibody for ALK (clone 5A4, Novocastra, 
Newcastle, UK), 1:100, was used for ALK fusion detection on 14 and 469 NSCLC tumor 
tissue sections (3 µm), respectively. Immunostaining of the slides was done on the 
BenchMark XT (Ventana Medical Systems, Inc.) using heat-induced epitope retrieval 
(HIER) in pretreatment buffer CC1 and OptiView DAB detection kit (Roche, Ventana 
Medical Systems, Inc.). The IHC staining results in Studies I, II, and IV were evaluated 
by experienced pathologists. 
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6.5 Fluorescence in situ hybridization (II, IV) 
In Studies II and IV, FISH was conducted for ALK fusion screening in 95 (from 87 
patients) and 171 NSCLC specimens, respectively. FISH was carried out on FFPE tumor 
tissue sections (2.5 µm) using the Vysis ALK Break Apart FISH Probe Kit (Abbott 
Molecular Inc., Des Plaines, IL, USA) according to the manufacturer´s instructions. 
Briefly, the tissue sections fixed on microscope slides were deparaffinized, pretreated 
with Vysis Pretreatment Solution and Protease Solution, denatured, hybridized with Vysis 
LSI ALK Dual Color Break Apart FISH probes, washed with Wash Buffers, and 
counterstained with DAPI (Abbott Molecular Inc.). StatSpin ThermoBrite Slide 
Processing System (Abbott Molecular Inc.) was used for the deparaffinization and 
hybridization steps. Using the fluorescence microscope Zeiss Axioskop 2 (Carl Zeiss 
Microscopy, LCC, Thornwood, NY, USA), at least two readers counted the number of 
orange, green, and fused signals in 50 nuclei per sample, and the average percentage of 
positive cells was recorded. A sample was defined as ALK-positive when ≥15% of the 
cells showed split green and orange signals or a deletion of green signal (5´end of the 
ALK). Cells containing adjacent or fused orange and green signals or single green signals 
were classified as ALK-negative. 
 
6.6 Real-time RT-PCR (II) 
In Study II, the presence of EML4-ALK gene fusion in 95 NSCLC specimens from 87 
patients was determined using the AmoyDx EML4-ALK fusion gene detection kit (Amoy 
Diagnostics, Xiamen, China), which contains reagents for detection of EML4-ALK 
variants 1, 2, 3a, 3b, 4, 4´, 5a, 5b, 5´, and 8, and the reference gene beta-actin in four 
different reactions. Reverse transcription of the extracted RNA (100-500 ng) and real-
time PCR on the ABI7500 instrument (Applied Biosystems, Foster City, CA, USA) were 
performed following the manufacturer´s instructions. A sample with a Ct value of ≤30 in 
an assay reaction was classified as EML4-ALK fusion-positive for one of the variants 
detected by that reaction. 
 
6.7 Real-time PCR (III) 
Real-time PCR assays were performed for validation of NGS results in Study III. EGFR 
mutations were screened in 81 NSCLC specimens using Therascreen EGFR PCR Kit 
(Qiagen®, Manchester, UK), which detects the following 28 EGFR mutations: 19 
deletions in exon 19, mutations L858R, L861Q, G719S/A/C (without distinguishing 
between them), S768I, and 3 insertions in exon 20 (without distinction). AmoyDx™ 
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BRAF V600E Mutation Detection Kit (Amoy Diagnostics) was used for detection of 
BRAF mutation V600E, and Therascreen KRAS PCR Kit (Qiagen) for detection of KRAS 
mutations G12A, G12D, G12R, G12C, G12S, G12V, and G13D in 78 NSCLC specimens. 
Kits for EGFR and KRAS mutation testing are based on ARMS® and Scorpions® 
technologies (Newton et al., 1989; Whitcombe et al., 1999; Thelwell et al., 2000), 
whereas the BRAF detection kit uses AmoyDx´s patented technology. All assays were 
done according to manufacturers´ instructions for the detection kits on an ABI7500 
instrument (Applied Biosystems). 
  
6.8 Targeted next-generation sequencing (II, III, IV) 
6.8.1 Targeted next-generation sequencing with Illumina HiSeq2000 system (II, III) 
Targeted NGS was conducted for detection of EML4-ALK fusion in 57 NSCLC 
specimens (from 56 patients) in Study II, and for detection of EGFR, KRAS, and BRAF 
mutations in 81 NSCLC specimens in Study III using Illumina sequencing technology. 
For capturing altogether 2676 target regions (~1 Mb), including all exons, 3´UTR, and 
5´UTR of selected 192 lung cancer-related genes, RNA baits (Agilent Technologies, 
Santa Clara, CA, USA) were designed with e-array (Agilent Technologies). Furthermore, 
for targeting all breakpoint variants of ALK fusion gene, baits capturing intronic region 
between exons 19 and 20 of ALK gene were also used. Agilent´s SureSelect in-solution 
target capture and enrichment protocol was applied for DNA (2-3 µg) fragmentation, 
adapter ligation, and target enrichment, followed by paired-end sequencing of the target-
enriched libraries on Illumina HiSeq2000 sequencer (Illumina, Inc., San Diego, CA, 
USA). Sequence data were analyzed using a variant-calling pipeline (VCP) developed at 
the Institute for Molecular Medicine Finland (FIMM) (Sulonen et al., 2011), consisting 
of quality filtering, sequence alignment with Burrows-Wheeler Aligner (BWA) (Li and 
Durbin, 2010), duplicate removal, and variant calling using SAMtools´ pileup (Li et al., 
2009), algorithms developed by FIMM, and read end anomaly (REA) calling. Pindel (Ye 
et al., 2009) was used for detection of indels, Circos (Krzywinski et al., 2009) for 
visualization of anomalously mapped paired-end (PE) reads (in Study II), and the 
Integrative Genomics Viewer (IGV) (Robinson et al., 2011) for visualization of sequence 
results. In Study III, the following thresholds were used in the VCP: quality score of ≥20, 
quality ratio of ≥0.8, and read depth of ≥6 in SNV calling, and quality value of ≥50 in 
indel calling. A cut-off of 3% was selected for variant calls. The sequence data processed 
with VCP were further sorted, and the final results of EGFR, KRAS, and BRAF genes 
included all SNVs leading to a splice variant, a non-synomymous amino acid change, or 
a premature stop codon, and all short indels leading to a frameshift or insertion/deletion 
of amino acids. For ALK fusion detection in Study II, anomalously mapped PE reads were 
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searched in all exons and the intronic region of ALK (chr2:29,446,208-29,448,431 in 
GRCh37 of the human reference genome). 
 
6.8.2 Targeted next-generation sequencing with Ion Torrent PGM system (IV) 
In Study IV, the Ion Torrent™ NGS technology (Life Technologies) was applied on 11 
ALK-rearranged NSCLC FFPE specimens for analysis of 90 hotspots and targeted 
regions in 22 genes (AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, 
FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, 
PTEN, SMAD4, STK11, TP53) using Ion AmpliSeq™ Colon and Lung Cancer Panel (Life 
Technologies). All steps of the protocol were performed according to the manufacturer´s 
instructions. Briefly, libraries were prepared from 10 ng of DNA with Ion AmpliSeq™ 
Library Kit 2.0 (Life Technologies) and quantified with Qubit® 2.0 Fluorometer (Life 
Technologies). Templates were prepared and enriched using Ion PGM™ Template 
OT2 200 Kit (Life Technologies) and Ion PGM™ Sequencing 200 Kit v2 (Life 
Technologies) on Ion OneTouch™ 2 system (Life Technologies). Sequencing was 
conducted using Ion 316™ v2 Chip on Ion Torrent™ Personal Genome Machine® 
(PGM, Life Technologies). Sequencing data were analyzed with Ion Torrent Suite™ 
Software v4.0.2 and Torrent Variant Caller Plugin v4.0, and visualized with IGV v2.2 
(Broad Institute). 
 
6.9 Sanger sequencing (III) 
In Study III, some NSCLC specimens showing novel mutations by NGS, or discordant 
results between NGS and real-time PCR, were further analyzed by Sanger sequencing. 
PCR-amplified DNA (12.5 ng) from nine NSCLC specimens and the corresponding 
normal lung tissue from five of these specimens were sequenced using Big-Dye 
Terminator v3.1 Cycle-sequencing Kit (Applied Biosystems, Warrington, UK) and ABI 
3730xl DNA sequencer (Applied Biosystems, Foster City, CA, USA). 
 
6.10 Statistical analyses (I, IV) 
The correlation between clinicopathological and molecular characteristics was assessed 
with Pearson´s χ2 test, Fisher´s exact test, or Mann-Whitney U test, as appropriate. All 
analyses were performed using SPSS PASW Statistics v18.0 (SPSS Inc., Chicago, IL, 
USA) in Study I and IBM SPSS Statistics v22 (IBM Corp., Armonk, NY, USA) in Study 
IV. Statistical significance was defined as two-sided p values of <0.05. 
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 Ethical permissions 
The study protocols were approved by the Ethics Committee for the Department of 
Surgery of the Hospital District of Helsinki and Uusimaa for Study I (consent no. 
394/13/03/02/10) and by the Ethics Committee for the Department of Medicine of the 
Hospital District of Helsinki and Uusimaa for Studies II-IV (consent no. 
370/13/03/01/10).  
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RESULTS AND DISCUSSION 
 
 Genetic and epigenetic profiling of diffuse gliomas (I) 
Characterization of molecular alterations in gliomas provides important information that 
enables more accurate glioma classification and prediction of prognosis and treatment 
response. The aims of this study were to evaluate the use of pyrosequencing on FFPE 
tumor tissue material and to molecularly characterize glioma subtypes by analyzing 
MGMT promoter hypermethylation, IDH1 mutation, and chromosomal copy number 
aberrations, and the associations between them. Survival analysis was not performed due 
to the relatively short follow-up time for the patients. 
 
8.1 Pyrosequencing in detection of MGMT promoter hypermethylation 
The MGMT promoter hypermethylation can be determined by various methods, each of 
them with advantages and limitations. For the assessment of MGMT methylation status, 
we performed pyrosequencing, which provides quantitative information of methylation 
at each studied CpG site. The challenge of quantitative methods is, however, the 
definition of a cut-off value separating the patients into methylated and unmethylated 
categories. Without a clear cut-off, there is a risk of patient misclassification. In our study, 
we used a cut-off of 9% for methylation (mean percentage of the five CpG sites studied), 
and further classified the methylated tumors as low methylated (9-29% of methylation) 
and highly methylated (>29% of methylation). These cut-offs were selected based on the 
observations by Dunn et al. (2009), who analyzed 12 CpG sites (including the five CpG 
sites examined in our study) and showed that MGMT methylation of >29% predicts better 
survival compared with lower methylation in glioblastoma patients, and that also 
methylation of 9-29% is associated with improved survival compared with methylation 
of <9%. Supporting the threshold of 9% for methylation, recently Quillien et al. (2014) 
validated this cut-off value for the mean methylation level across the five CpG sites 
sequenced in the commonly used commercial pyrosequencing test, applied also in our 
series. Quillien et al. (2014) showed that methylation of 9% serves as the best threshold 
value, dividing patients into groups of better (methylated MGMT) and poorer 
(unmethylated MGMT) survival. 
Consistent with earlier (Mikeska et al., 2007; Dunn et al., 2009) and more recent 
(published after our paper) studies (Quillien et al., 2012) showing the applicability of 
pyrosequencing in FFPE specimens, we performed pyrosequencing successfully on FFPE 
sample material. Moreover, we detected a similar degree of methylation in three replicates 
and their corresponding tumor samples included in the analysis. Thus, our results further 
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support the use of pyrosequencing in the testing of MGMT promoter hypermethylation in 
FFPE glioma specimens. Many studies have shown the robustness and good predictive 
value of pyrosequencing in the assessment of MGMT methylation status (Mikeska et al., 
2007; Dunn et al., 2009; Karayan-Tapon et al., 2010; Havik et al., 2012; Quillien et al., 
2012). However, the expensive equipment and the relatively high cost per sample when 
only a few samples are analyzed at a time are possible limitations to the use of 
pyrosequencing in routine molecular diagnostics.  
 
8.2 Chromosomal copy number aberrations, IDH1 mutation and MGMT 
promoter hypermethylation in glioma subtypes 
Chromosomal copy number aberrations were identified by array CGH in all studied 
gliomas, the majority (73.8%) of them carrying three or more aberrations. The most 
recurrent copy number changes detected were losses at chromosomes 1p, 4q, 9p, 10q, 
13q, 14q, 18, 19q, and 22q, and gains at chromosome 7 (Figure 1 in Study I). Losses of 
1p and 19q, together and separately, were significantly associated with oligodendroglial 
morphology (p≤0.001) and tumor grades II-III (p<0.01) (Table 2 in Study I). Losses of 
9p and 10q, with most frequently deleted regions of 9p21.3 (including CDKN2A/p16 
gene), 10q26.13-26.2, and 10q25.3qter (including MGMT gene), were strongly linked to 
glioblastomas (p<0.05, p<0.01, and p<0.001, respectively) and tumor grade IV (p≤0.001). 
These findings are in concordance with the literature (Reifenberger et al., 1994; Ohgaki 
et al., 2004). We also detected a significant correlation (p<0.001) between astrocytomas 
(grades II-III) and loss of 13q14.3-21.33, although the number of astrocytomas included 
in Study I was small (n=3). 
The presence of IDH1 mutation was detected by IHC in 64.7% of all gliomas, showing a 
significant association with oligodendroglial tumors (p<0.001) and tumor grades II-III 
(p<0.001) (Table 3 in Study I). IDH1 mutation was identified in 93.3% of 
oligodendrogliomas, 88.9% of oligoastrocytomas, 66.7% of astrocytomas, and only 6.7% 
of glioblastomas. These observations are in line with previous studies reporting IDH1 
mutations predominantly in diffuse gliomas grade II-III and secondary glioblastomas 
(Balss et al., 2008; Yan et al., 2009). 
Among analyzed gliomas, 82.4% showed MGMT promoter methylation by 
pyrosequencing, with a significant association emerging with glioma subtype (p<0.001) 
and grade (p<0.001) (Table 3 in Study I). All oligodendroglial tumors (grades II-III), 
excluding one oligodendroglioma (grade II), showed either low or high methylation. 
Also, all grade II and III astrocytomas had a methylated MGMT. In glioblastomas (grade 
IV), MGMT methylation was detected in 46.7% of the cases. Similar frequencies of 
MGMT methylation have been previously described in glioblastomas (Hegi et al., 2004; 
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Hegi et al., 2005; Eoli et al., 2007; Dunn et al., 2009; Jha et al., 2010), but compared with 
reported frequencies of 47-88% in oligodendrogliomas (Dong et al., 2001; Watanabe et 
al., 2002; Alonso et al., 2003; Mollemann et al., 2005; Jha et al., 2010), 64-83% in 
oligoastrocytomas (Dong et al., 2001; Alonso et al., 2003; Mollemann et al., 2005; Jha et 
al., 2010), and 43-50% in astrocytomas (Komine et al., 2003; Wick et al., 2009), the other 
glioma subtypes presented higher MGMT methylation in our study. These differences 
might be due to the varying sensitivities of detection methods used, e.g. the capability of 
quantitative pyrosequencing technology to detect also low methylation, which the 
commonly used MSP might miss (Weller et al., 2010). 
 
8.3 Associations between genetic and epigenetic alterations 
We found a significant correlation between MGMT hypermethylation and IDH1 mutation 
(p=0.001) (Table 3 in Study I), confirming previous observations (Sanson et al., 2009; 
Hartmann et al., 2010; van den Bent et al., 2010; Mellai et al., 2011). Mutated IDH1 is 
suggested to predispose MGMT and many other genes to hypermethylation by producing 
2-hydroxyglutarate, which inhibits various α-ketoglutarate-dependent enzymes, further 
leading to histone and DNA methylation aberrations (Dang et al., 2009; Noushmehr et 
al., 2010; Xu et al., 2011). Simultaneous screening for both MGMT hypermethylation and 
IDH1 mutations is supported by recent studies that have suggested a better prediction of 
the survival of glioblastoma patients when both statuses are assessed (Molenaar et al., 
2014), and a better survival of high-grade glioma patients with MGMT hypermethylation 
and non-mutated IDH1, as opposed to MGMT hypermethylation and mutated IDH1, when 
treated with alkylating agent chemotherapy (Wick et al., 2013). 
Methylated MGMT was also significantly associated with loss of 19q (p<0.05), and 
although a trend towards an association of MGMT methylation with losses of 1p and 
combined loss of 1p/19q was seen, it did not reach statistical significance (Table 2 in 
Study I). Earlier, significant associations of MGMT hypermethylation and losses of 
1p/19q have been described in many studies (Dong et al., 2001; Mollemann et al., 2005; 
Brandes et al., 2006; van den Bent et al., 2009; Yang et al., 2009), while other studies 
have reported no such associations (Watanabe et al., 2002; Everhard et al., 2006; Kuo et 
al., 2009; Jha et al., 2010). 
Tumors lacking MGMT hypermethylation were characterized by significant associations 
with losses on chromosomes 9p21.3 (p<0.05), 10q26.13-26.2 (p<0.05), and 10q25.3qter 
(p<0.01) as well as a gain on chromosome 7p (p<0.05) (Table 2 in Study I). Eoli et al. 
(2007) have reported amplification of the EGFR gene, located on chromosome 7p, to 
occur more frequently in unmethylated glioblastomas than in methylated ones, although 
no significant association was observed, whereas Jha et al. (2010) found no association 
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between them. Unlike earlier studies (Felsberg et al., 2009; Kuo et al., 2009) showing no 
association between MGMT hypermethylation and loss of 10q, we detected an intriguing 
correlation of unmethylated MGMT with loss of chromosome 10q25.3qter, encompassing 
the MGMT gene locus. This finding implicates that MGMT downregulation is important 
for glioma progression; if not by hypermethylation, MGMT could be silenced by 
alternative genetic mechanisms such as deletion of the chromosome region where the 
gene is located. Interestingly, a recent study (published after our paper) not only showed 
that both MGMT methylation and monosomy/deletion of MGMT locus (together 
presenting the lowest MGMT mRNA expression levels) are needed for effective MGMT 
downregulation, but also suggested that the effect of monosomy or MGMT deletion on 
the MGMT transcript levels is emphasized specifically in gliomas lacking MGMT 
promoter methylation (Ramalho-Carvalho et al., 2013). 
In agreement with previous studies (Sanson et al., 2009; Labussiere et al., 2010), we also 
detected a significant association of IDH1 mutation with losses of 1p (p<0.05) and 1p/19q 
codeletion (p<0.01) (Table 2 in Study I). Furthermore, in comparison with IDH1-positive 
tumors, tumors lacking IDH1 mutation carried more frequently losses of 10q25.3qter 
(p<0.01) and 10q26.13-26.2 (p<0.05). Table 3 presents a summary of all significant 
associations identified in this study between glioma subtype, grade, MGMT 
hypermethylation, IDH1 mutations, and chromosomal aberrations. 
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      Table 3. Summary of significant associations (p<0.05) detected in the study. 
 A significant association with 
Glioma subtype 
     Astrocytomas (n=3) 
 
     Oligodendroglial tumors (oligodendrogliomas and  
oligoastrocytomas) 
 
 
     Glioblastomas 
 
13q14.3-21.33 loss 
 
1p loss 
19q loss 
Combined 1p/19q loss 
 
9p21.3 loss 
10q26.13-26.2 loss 
10q25.3qter loss 
WHO grade 
     II-III 
      
      
 
     IV 
 
1p loss 
19q loss 
Combined 1p/19q loss 
 
9p21.3 loss 
10q26.13-26.2 loss 
10q25.3qter loss 
MGMT methylation 
     Methylated MGMT (>9% of methylation) 
     
 
 
 
     Unmethylated MGMT (<9% of methylation) 
 
Oligodendroglial morphology 
Grades II-III 
IDH1 mutation 
19q loss 
 
9p21.3 loss 
10q26.13-26.2 loss 
10q25.3qter loss (MGMT) 
7p gain 
IDH1 mutation 
     Mutated IDH1 
 
     
    
     
      
     Non-mutated IDH1 
 
 
Oligodendroglial morphology 
Grades II-III 
MGMT methylation 
1p loss 
Combined 1p/19q loss 
 
10q25.3qter loss 
10q26.13-26.2 loss 
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 Next-generation sequencing in detection of genetic alterations in non-
small cell lung cancer (II, III) 
Various methods are available for identification of clinically relevant genetic alterations. 
However, the possibility to evaluate multiple alterations simultaneously renders NGS 
highly beneficial in screening for biomarkers with predictive and prognostic value. The 
aim of Studies II and III was to evaluate the applicability of targeted NGS (Illumina 
HiSeq2000 system) on screening for ALK fusions, and EGFR, KRAS, and BRAF 
mutations on FFPE NSCLC specimens by comparing NGS results with results from 
FISH, IHC, real-time RT-PCR, and real-time PCR. Moreover, using NGS we aimed to 
find novel mutations not included in the PCR panels used (Study III).  
 
9.1 Correlation of targeted NGS with FISH, IHC, real-time RT-PCR, and 
real-time PCR in detection of genetic alterations (II, III) 
For ALK fusion screening, we studied altogether 87 NSCLC patients, for whom all 
samples were analyzed by FISH and real-time RT-PCR, 56 samples by targeted NGS, 
and 14 samples by IHC (Study II). EGFR mutation status was assessed in 81 patients and 
KRAS and BRAF mutation statuses in 78 patients by targeted NGS and real-time PCR 
(Study III). Although the use of FFPE tumor tissue material might be challenging, we 
obtained successful and interpretable results for all samples, thus supporting the 
feasibility of FFPE in the analyses. Also, concordant results were observed between eight 
replicate and their corresponding samples included in Study II.  
The results of ALK fusion screening showed an excellent concordance between targeted 
NGS, FISH, IHC, and real-time RT-PCR; no discrepant results were detected (Table 4). 
Also in EGFR, KRAS, and BRAF mutation screening, the concordance of the results 
between targeted NGS and real-time PCR was very good; 96.3% in EGFR, 98.7% in 
KRAS, and 100% in BRAF detection (Table 1 in Study III). Although the same DNA 
samples were used with both methods, real-time PCR revealed four mutations, three in 
EGFR (Leu858Arg, Leu861Gln, and Ser768Ile) and one in KRAS (Gly12Asp), which 
were not detected by targeted NGS (Table 3 in Study III; Table 4). Possible explanations 
for these discrepant results could be the higher sensitivity of PCR than of NGS, especially 
in the case of low number of total reads as detected in two of the cases (0/21 variant/total 
reads for Leu858Arg and 1/41 variants/total reads for Leu861Gln), or a potential biased 
enrichment of wild-type allele instead of the variant allele by hybridization-based 
enrichment of NGS. Overall, the average sequencing coverages of EGFR, KRAS, and 
BRAF were 193, 177, and 206, respectively. On the other hand, PCR-based methods 
might be prone to false-positive results. Sanger sequencing did not reveal mutations in 
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three of the four discrepant cases (one of them was not tested due to lack of DNA), thus 
confirming the NGS results. Noteworthy is, however, that Sanger sequencing is 
considered less sensitive than real-time PCR. 
 
Table 4. Comparison of the detection of ALK fusion and EGFR, KRAS, and BRAF mutations by 
targeted next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), 
immunohistochemistry (IHC), real-time reverse transcription-polymerase chain reaction (RT-PCR), 
and real-time PCR. 
Variant Targeted 
NGS 
FISH IHC Real-time 
RT-PCR 
Real-time 
PCR 
Discrepant cases 
between methods 
ALK fusion 
     All 
     ALK+ 
     ALK- 
 
56 
4* 
52 
 
87 
5 
82 
 
14 
5 
9 
 
87 
5 
82 
 0 
 
 
EGFR mutation 
     All 
     EGFR+ 
     EGFR- 
 
81 
15 
66 
    
81 
18 
63 
3 
 
 
KRAS mutation 
     All 
     KRAS+ 
     KRAS- 
 
78 
24 
54 
    
78 
25 
53 
1 
 
 
BRAF mutation 
     All 
     BRAF+ 
     BRAF- 
 
78 
0 
78 
    
78 
0 
78 
0 
 
 
*The fifth ALK+ patient was not analyzed by targeted NGS 
 
Important requirements for a testing method to be used in cancer diagnostics are 
specificity, sensitivity, feasibility of FFPE tumor tissue specimens, low amount of input 
DNA required, short turnaround time, and low cost. All methods used in Studies II and 
III have advantages and limitations. Table 2 in Study II presents a comparison of the 
characteristics of FISH, IHC, real-time RT-PCR, and NGS in screening of ALK fusion. 
Using targeted NGS, we could screen ALK fusions, EGFR, KRAS, and BRAF mutations, 
and also multiple other variations in a single sequencing run, not possible with any other 
method used. Another advantage of NGS over the other methods is its accuracy in 
detecting fusion variants, as seen in Study II; by IHC and FISH, specification of the ALK 
fusion variant or even the fusion partner was not possible and by RT-PCR the ALK fusion 
variant could be confined among variants 1, 2, and 3a/3b but not distinguished between 
them, whereas by NGS the exact breakpoint in intronic regions between exons 19 and 20 
of ALK, and intron 13 in EML4, corresponding to variant 1, could be identified. The lack 
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of anomalously paired reads in ALK region in the ALK-negative cases support also the 
specificity of targeted NGS in the detection of ALK fusions.  
Although we could not determine the definite sensitivity of NGS by dilution series due to 
the limited amount of tumor material, the concordant results between NGS and the other 
methods used support its sensitivity. PCR-based methods, real-time RT-PCR and PCR, 
are generally highly sensitive. Also, the same antibody to ALK, clone 5A4, by which we 
detected a strong staining reaction in all ALK-positive cases, has proved to be sensitive 
in the identification of ALK fusions in lung carcinomas (Paik et al., 2011a; Just et al., 
2012; McLeer-Florin et al., 2012; Paik et al., 2012; Conklin et al., 2013). By the well-
standardized dual-color break apart FISH assay, we observed two different signal patterns 
of ALK-positive cases, deleted green signal in three and split orange and green signals in 
two of the cases. Because interpretation of FISH results is prone to variability between 
viewers (Wallander et al., 2012), our results were interpreted by two experienced viewers. 
The importance of evaluation of the results by more than one reader was revealed with 
one borderline case (20% of positive cells by first reader), which was after evaluation by 
two additional readers eventually classified as negative (<15% of positive cells), in 
accordance with the results obtained by IHC, real-time RT-PCR, and targeted NGS.  
Diagnostic lung cancer samples are often formalin-fixed and paraffin-embedded 
specimens, small biopsies or fine needle aspirations. The amount of DNA/RNA that can 
be isolated from these specimens might be very low, and the DNA/RNA isolated from 
FFPE material is generally degraded and fragmented. Thus, the analysis of FFPE 
specimens might be challenging. In our studies, however, all methods used were 
applicable on FFPE tumor tissue material. 
The prevalently used analysis methods, FISH, IHC, and PCR-based methods, are highly 
advantageous because only a small amount of tumor tissue material is required and the 
turnaround time and cost are reasonable. The clear limitations of the Illumina HiSeq2000 
system applied for targeted NGS comprise the requirement of 2-3 µg of DNA for the 
analysis, the turnaround time of around 10 days, expensive equipment, and the high cost 
per sample. Moreover, compared with the other methods studied, NGS data analysis is 
challenging without expertise in bioinformatics. Thus, although targeted NGS application 
provides a useful tool for cancer diagnostics by enabling the identification of all clinically 
relevant gene alterations simultaneously in a single test, thereby saving time and material, 
this platform is not optimal for diagnostics use.  
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9.2 ALK fusion and mutations in EGFR, KRAS, and BRAF in 
adenocarcinoma-enriched NSCLC patient cohorts (II, III) 
The presence of ALK fusion was found in five (5.7%) of the 87 NSCLC patients analyzed 
in Study II. EGFR, KRAS, and BRAF mutations were detected in 18.5% (15/81), 30.8% 
(24/78), and 0% (0/78) by targeted NGS, and 22.2% (18/81), 32.1% (25/78), and 0% 
(0/78) by real-time PCR, respectively. The frequency of EGFR mutations was a bit higher 
if those mutations identified by NGS but not by PCR were included, being 24.7% (20/81). 
Our results regarding the prevalence of ALK fusion and EGFR and KRAS mutations 
among selected adenocarcinoma-enriched NSCLC patients are in agreement with the 
literature (Pao and Miller, 2005; Koivunen et al., 2008; Martelli et al., 2009; Rodig et al., 
2009; Wong et al., 2009; Brandao et al., 2012). The lack of BRAF mutations in our rather 
small study population enriched with adenocarcinomas and non-smokers is probably due 
to BRAF mutations usually occurring in NSCLCs at a low frequency (~3%) and 
predominantly being seen in smokers (Brose et al., 2002; Davies et al., 2002; Marchetti 
et al., 2011; Paik et al., 2011b). Consistent with other reports (Siegfried et al., 1997; 
Ladanyi and Pao, 2008; Murray et al., 2008; Sasaki et al., 2010), we detected most 
frequently the following variants: Leu858Arg and deletions in exon 19 in EGFR, 
Gly12Cys, Gly12Val, and Gly12Asp in KRAS (Table 2 in Study III), and variant type 1 
of EML4-ALK fusion, which was present in all ALK-positive cases (Table 1 in Study II). 
Other mutations identified included Leu861Gln and Ser768Ile in EGFR and Gly12Ala 
and Gly12Arg in KRAS. 
All patients harboring EGFR mutations had adenocarcinoma histology and most of them 
(73.9%) were female. Also all KRAS mutant patients had adenocarcinoma, but no 
remarkable gender difference among KRAS mutation carriers was seen (56% females vs. 
44% males). These results are supported by earlier findings according to which mutations 
in EGFR and KRAS are linked to adenocarcinomas, and EGFR mutations also to female 
gender (reviewed by Pao and Miller, 2005; Brandao et al., 2012). The clinicopathological 
characteristics associated with ALK fusion were investigated more comprehensively in 
Study IV and will be discussed later. 
In NSCLCs, ALK fusions usually occur in the absence of EGFR and KRAS mutations 
(Inamura et al., 2009; Shaw et al., 2009; Wong et al., 2009; Takahashi et al., 2010; Zhang 
et al., 2010; McLeer-Florin et al., 2012; Wallander et al., 2012; Gainor et al., 2013), 
EGFR mutations in the absence of KRAS mutations (Kosaka et al., 2004; Shigematsu et 
al., 2005), and BRAF mutations in the absence of all of the above-mentioned (Paik et al., 
2011b), although some co-occurrences have been reported (Eberhard et al., 2005; Han et 
al., 2006; Zhu et al., 2008; Martelli et al., 2009; Tiseo et al., 2011; Li et al., 2014a). We 
observed ALK fusion to be mutually exclusive of EGFR mutations in Study II, and while 
most of the tumors harboring EGFR mutations lacked KRAS mutations in Study III, two 
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tumors with concurrent EGFR and KRAS mutations were detected. Moreover, five tumors 
showed two or three co-occurring EGFR variants.  
 
9.3 Detection of rare and novel mutations by targeted NGS (III) 
In addition to providing information on numerous common genetic alterations, NGS 
enables the detection of novel and rare ones. In Study III, targeted NGS revealed seven 
SNVs and one indel in EGFR that were not detectable by the PCR panel used, four of 
which were previously unreported (Table 5). The identified mutations included three 
point and one insertion mutations in exon 20, and one point mutation in each of the exons 
2, 7, 17, and 21. By Sanger sequencing, only variants Ala647Thr in exon 17 and 
Pro848Leu in exon 21 could be validated; for others, interpretable results were not 
obtained due to high background noise. The variant Ala647Thr was detected also in the 
corresponding normal tissue, suggesting its germline origin.  
 
Table 5. Non-synonymous SNVs and indels in the EGFR gene identified by targeted next-
generation sequencing, not detectable by real-time PCR. 
Amino acid change Exon Protein domain No. of 
patients 
Previously described mutations 
     Leu62Arg 
     His773Leua 
     Val774Meta 
     Pro848Leub 
 
2 
20 
20 
21 
 
Extracellular (receptor L domain) 
Protein kinase 
Protein kinase 
Protein kinase 
 
1 
1 
1 
1 
Novel mutations 
     Tyr275Phe 
     Ala647Thrb 
     Ala767_Ser768ins_SerValGly 
     His773Pro 
 
7 
17 
20 
20 
 
Extracellular (furin-like Cys-rich domain) 
Transmembrane 
Protein kinase 
Protein kinase 
 
2 
1 
1 
3 
  aCoexisting variants in the same haplotype in the same patient 
  bVariants validated by Sanger sequencing 
 
 
Exon 20 mutations were the most common mutations, present in four cases; three were 
missense mutations (His773Pro, His773Leu, and Val774Met) and one an insertion 
mutation (Ala767_Ser768_insSerValGly). Although other variants have been found in 
the same amino acid positions, variants His773Pro and Ala767_Ser768_insSerValGly 
have not been previously reported. The potential value of the exon 20 mutations and the 
other EGFR mutations identified in our study for the determination of prognosis and 
treatment response is unknown and remains to be elucidated in future studies, but 
interestingly we detected a primary resistance towards EGFR TKI erlotinib in a patient 
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harboring the Ala767_Ser768_insSerValGly variant. In contrast to the most common 
EGFR mutations, i.e. exon 19 deletions and point mutation Leu858Arg (L858R) in exon 
21 with a sensitivity to TKI treatment, the point and insertion mutations in exon 20 have 
been associated with resistance or lower response to EGFR TKI treatment and poorer 
prognosis (Kobayashi et al., 2005; Pao et al., 2005; Wu et al., 2008; De Pas et al., 2011; 
Wu et al., 2011; Lund-Iversen et al., 2012; Yasuda et al., 2012; Oxnard et al., 2013; Beau-
Faller et al., 2014; Woo et al., 2014). Furthermore, some rare EGFR mutations, including 
Pro848Leu, present also in our study, have been linked to lack of response to EGFR TKI 
treatment (Sequist et al., 2007; Han et al., 2011). Screening not only the sensitizing 
mutations but also the rather rare mutations potentially linked to resistance to treatment 
is beneficial when choosing optimal treatment for patients, and NGS provides a highly 
valuable tool for this purpose. 
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 Clinicopathological and molecular characterization of non-small cell 
lung cancer patients harboring ALK fusion (IV) 
The predictive value of ALK fusion in NSCLC patients makes it an important biomarker 
for screening. The aim of this study was to determine the previously unknown frequency 
of ALK fusion in Finnish NSCLC patients by IHC, validate the IHC results by FISH, and 
further characterize the ALK fusion-positive cases by examining their clinicopathological 
features and the coexistence of mutations in 22 other driver genes using the targeted NGS 
technology (Ion Torrent PGM system). IHC was selected for ALK fusion detection 
because it is a rapid and affordable method for screening multiple samples. Survival 
differences between ALK-positive and ALK-negative patients could not be reliably 
analyzed due to differences in patients´ clinical characteristics, such as stage of lung 
cancer and treatment received, between genotype groups. 
 
10.1 ALK fusion frequency in Finnish NSCLC patients 
Using IHC, we detected the presence of ALK protein expression in 11 (2.3%) of 469 
NSCLC tumors, whereas no expression was observed in any other tumors. Concordant 
results were detected by FISH in all 171 specimens tested, including 11 ALK-positive 
and 160 random ALK-negative cases, further supporting the good correlation between 
the ALK fusion detection methods observed in Study II.   
The ALK fusion was present in 2.3% of unselected NSCLC patients, which is a lower 
frequency than that in Study II, where ALK fusion was detected in 5.7% of NSCLC 
patients enriched by adenocarcinoma histology. These frequencies are well in line with 
the literature reporting on average a higher ALK fusion frequency in adenocarcinoma-
enriched patients (4.5%) than in unselected ones (3%) (reviewed by Bang, 2011). Despite 
the special features of the Finnish population, such as founder effect, genetic drift, and 
genetic isolation, which likely affect the prevalence of genetic alterations within the 
population, we identified a very similar frequency of ALK fusion as that reported for 
Japanese (2.3%, 5/221; Inamura et al., 2008), American/Korean (2.6%, 8/305; Koivunen 
et al., 2008), and American/Swiss cohorts (2.7%, 16/603; Perner et al., 2008). Since the 
frequency of ALK fusion among Finnish NSCLC patients does not differ markedly from 
the frequencies in other cohorts, we conclude that the prevalence of ALK fusion seems to 
be similar regardless of ethnic background. 
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10.2 Clinicopathological characteristics of patients harboring ALK fusion 
Our results show that in comparison with patients lacking ALK fusion, ALK-positive 
patients appear to be younger (median age of 51 years vs. 66 years, p=0.004) and either 
never- (7/11) or ex-light smokers (4/11; p<0.001) (Table 1 in Study IV). These findings 
are in line with previous observations (Rodig et al., 2009; Shaw et al., 2009; Wong et al., 
2009; Takahashi et al., 2010). Other studied clinicopathological characteristics, including 
sex, tumor histology, and occupational asbestos exposure did not differ significantly 
between ALK-positive and ALK-negative patients. Although ALK fusion is commonly 
linked to adenocarcinoma histology (Shaw et al., 2009; Wong et al., 2009; Takahashi et 
al., 2010), as also in our study where the majority (9/11) of ALK-positive cases were 
adenocarcinomas, we identified two (5.7%) of 35 large cell carcinomas carrying an ALK 
fusion. Both of these patients had male gender, never-smoking history, young age at 
diagnosis (44 and 47 years, respectively), metastatic disease, and survival time ~11 
months. This finding together with recent studies also showing the occurrence of ALK 
rearrangements in large cell carcinomas (Rekhtman et al., 2013; Rossi et al., 2014) 
emphasizes that, in addition to adenocarcinomas, ALK fusion screening should also be 
performed on large cell carcinomas. 
Classification of ALK-positive adenocarcinomas by the classification strategy presented 
by Travis et al. (2011) showed that all nine adenocarcinomas were invasive 
adenocarcinomas with varying histologic growth patterns; solid features were detected as 
the predominant pattern in three, acinar in two, micropapillary in two, papillary in one, 
and lepidic in one of the tumors (Table 2 in Study IV). The rather low number of ALK-
positive cases in our study might explain why no growth pattern predominated over the 
others. Recently, Yoshida et al. (2011a) did not detect any histomorphologic feature to be 
fully sensitive and specific to ALK fusion, although the presence of a “solid signet-ring 
cell pattern” and a “mucinous cribriform pattern” was observed in the majority of ALK-
positive tumors.  
 
10.3 Presence of other driver gene mutations in NSCLC patients harboring 
ALK fusion 
The identification of mutations in 22 lung and colon cancer-related genes in 11 ALK-
positive NSCLC tumors by Ion Torrent NGS technology revealed ALK fusion 
concurrently with MET mutation in four, TP53 mutation in two, CTNNB1 mutation in 
one, and PIK3CA mutation in one of the tumors (Table 3 in Study IV). The identified 
MET mutations (Thr992/1010Ile in two and Asn375Ser in two of the tumors), CTNNB1 
mutation (Ser45Pro), and the other TP53 mutation (Arg114/141/234/273His) were known 
hotspot mutations, whereas mutation in PIK3CA (Ile534fs) and the other detected TP53 
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mutation (Ile92/119/212/251Met) were novel ones (not reported in dbSNP or the 
Catalogue Of Somatic Mutations In Cancer (COSMIC)). Altogether, the presence of non-
synonymous mutations in the driver genes studied was detected in seven tumors, one of 
them carrying both MET and CTNNB1 mutations.  
ALK fusion is typically reported to be mutually exclusive of mutations in other driver 
genes, including EGFR, KRAS, TP53, PIK3CA, and CTNNB1 (Inamura et al., 2009; 
Wong et al., 2009; Sun et al., 2010; Zhang et al., 2010; Sequist et al., 2011; Gainor et al., 
2013; Li et al., 2013; Okamoto et al., 2014; Serizawa et al., 2014; Wang et al., 2014). 
However, consistent with our findings, concurrent MET, TP53, and PIK3CA mutations 
have also been found in some ALK-positive NSCLCs (Inamura et al., 2009; Chaft et al., 
2012; Boland et al., 2013). The co-occurrence of ALK fusion, MET mutation, and 
CTNNB1 mutation, which we observed in one NSCLC tumor, has not been reported 
previously. Identification of the significance of the co-occurrences of ALK fusion with 
MET, TP53, CTNNB1, and PIK3CA mutations requires further studies. As crizotinib is 
also a MET inhibitor, it will be of great interest to investigate whether patients carrying 
both ALK and MET alterations have an increased benefit from crizotinib treatment. 
In our study, the most frequently mutated gene in ALK-rearranged tumors was MET, in 
which we detected two different mutations, Asn375Ser within the semaphorin domain 
and Thr992/1010Ile within the juxtamembrane domain. Earlier studies have shown that 
the most frequently seen MET mutation in lung cancer, Asn375Ser, is germline and the 
cells carrying the mutation seem to lack sensitivity to inhibition of MET signaling (Tengs 
et al., 2006; Krishnaswamy et al., 2009; Tanizaki et al., 2011). Thr992/1010Ile has been 
described as a mutation with transforming potential in SCLC (Ma et al., 2003) and 
NSCLC (Tengs et al., 2006), although contrary results have been reported in some other 
cancers (Tyner et al., 2010). Using the SIFT tool (Kumar et al., 2009) for prediction of 
the effect of mutations on protein function, Asn375Ser was considered as a tolerated 
mutation and Thr992/1010Ile as a damaging mutation. Unfortunately, since DNA from 
adjacent normal tissue was not available, we could not determine whether the mutations 
detected in our study were somatic or germline in origin. 
Table 6 summarizes the relationships between ALK fusion and the clinicopathological 
and molecular characteristics examined in this study. 
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Table 6. Presence of clinicopathological characteristics and other driver gene mutations in     
ALK-rearranged non-small cell lung cancer patients. 
Characteristic ALK-positive 
patients (n=11) 
% 
Age 
     Median 
     Range 
 
51 
44–74 
 
Sex 
     Female 
     Male 
 
5 
6 
 
45.5 
54.5 
Tumor histology 
     Adenocarcinoma 
     Squamous cell carcinoma 
     Large cell carcinoma 
     Other NSCLC subtype or not otherwise specified 
 
9 
0 
2 
0 
 
81.8 
0 
18.2 
0 
Predominant growth pattern of adenocarcinomas (n=9) 
     Acinar 
     Lepidic 
     Micropapillary 
     Papillary 
     Solid 
 
2 
1 
2 
1 
3 
 
18.2 
11.1 
18.2 
11.1 
33.3 
Tumor stage 
     I 
     II 
     III 
     IV 
 
3 
4 
0 
4 
 
27.3 
36.4 
0 
36.4 
Smoking history 
     Never-smokers 
     Ex-light smokers 
     Ex-medium smokers 
     Current smokers 
 
7 
4 
0 
0 
 
63.6 
36.4 
0 
0 
Occupational asbestos exposure 
     Exposed 
     Non-exposed 
 
0 
11 
 
0 
100 
Other driver gene mutations (amino acid change) 
     MET (Asn375Ser, Thr992/1010Ile) 
     TP53 (Arg114/141/234/273His, Ile92/119/212/251Met) 
     CTNNB1 (Ser45Pro) 
     PIK3CA (Ile534fs) 
     No other mutations 
 
4 
2 
1 
1 
4 
 
36.4 
18.2 
9.1 
9.1 
36.4 
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CONCLUSIONS 
 
In this thesis, molecular profiling of diffuse gliomas and NSCLCs was performed using 
various methods. In Study I, using pyrosequencing, IHC, and array CGH, we showed 
variation in the presence of MGMT methylation, IDH1 mutation, and chromosomal 
aberrations among glioma subtypes and grades. MGMT methylation was significantly 
associated with IDH1 mutation, chromosome 19q loss, and oligodendroglial phenotype, 
whereas unmethylated MGMT was linked to losses on 9p and 10q and gain on 7p. 
Furthermore, we detected associations of IDH1 mutation with losses on 1p and 1p/19q 
and non-mutated IDH1 with losses on 10q. Pyrosequencing proved to work well in the 
identification of MGMT hypermethylation in glioma samples from FFPE material. By 
comparing targeted NGS with the commonly used methods of FISH, IHC, real-time RT-
PCR, and real-time PCR in Studies II and III, we showed that targeted NGS is a suitable 
tool for detection of ALK fusion and EGFR, KRAS, and BRAF mutations in FFPE NSCLC 
specimens. Alongside the identification of known predictive biomarkers, our study 
indicated the benefits of NGS in the detection of rare and novel genetic variants, which 
might also contribute to sensitivity or resistance towards targeted therapy. The screening 
of ALK-positive NSCLC patients by cost-effective IHC in Study IV showed ALK fusion 
to be a rather rare alteration, present in 2.3% of Finnish NSCLC patients.  Furthermore, 
ALK-positive patients were characterized by a relatively young age, never-/ex-light 
smoking history, adenocarcinoma but also large cell carcinoma histology, varying 
mixture of histological subtypes of adenocarcinomas, almost equal sex distribution, and 
lack of occupational asbestos exposure. Using targeted NGS, we found that mutations in 
certain driver genes, including MET, TP53, CTNNB1, and PIK3CA, occurred together 
with ALK fusion. All of the rare and novel variants identified in this thesis can serve as 
targets for future studies, in which their potential clinical value could be evaluated. 
Some cancer patients benefit from targeted therapy because they carry certain genetic or 
epigenetic alterations, making their tumors sensitive to the treatment. However, the 
simultaneous presence of some other alteration(s) in the tumor genome might lower the 
response or even lead to resistance towards the therapy. Thus, the integration of 
information of multiple genetic and epigenetic changes provides a better insight into the 
molecular background of the tumors, which may help in the prediction of tumor behavior, 
prognosis, and treatment response. As shown here, some alterations occurred together in 
diffuse gliomas and NSCLCs, and although we could not study the clinical significance 
of these co-occurring alterations, they may contribute to the success of targeted 
treatments. 
Currently, various methods are available for detection of genetic and epigenetic changes 
in cancer patients. Each of them has benefits and limitations in terms of cost, amount of 
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material required, analysis time, sensitivity, specificity, ease of performance, data 
analysis, and interpretation of the results. In this thesis, we showed the value of 
pyrosequencing in MGMT methylation testing in diffuse gliomas, and targeted NGS in 
the detection of genetic alterations in NSCLCs, but both of these technologies also have 
limitations. Pyrosequencing is an expensive technology and the cut-off used for MGMT 
methylation is not firmly established. The Illumina HiSeq2000 platform, applied in 
Studies II and III, is also an expensive system requiring a large amount of DNA (2-3 µg), 
a lengthy analysis (~10 days), and expertise in data analysis and interpretation of results. 
These limitations of the HiSeq2000 system are, however, overcome in other NGS 
platforms, such as in the Ion Torrent PGM system, which we used in Study IV. The latter 
system´s analysis workflow is cheaper, faster (~3 days), simpler, and requires less DNA 
(~10 ng), and thus is even better suited to FFPE sample material and diagnostics use. The 
rapid development seen in recent years in the field of NGS is anticipated to continue, 
resolving the limitations of current NGS technologies via novel technologies.  
In the future, NGS technology will likely replace, at least to some extent, the current 
routinely used methods, including FISH, IHC, and PCR-based methods, in clinical 
diagnostics. The great benefit of targeted NGS over the other available methods is the 
possibility to simultaneously screen all known predictive biomarkers. Furthermore, as 
novel clinically significant biomarkers are identified, they could be added to the existing 
biomarker panels. Besides detection of ALK fusions and mutations in EGFR, KRAS, and 
BRAF as shown in this thesis, also fusions and mutations in other genes as well as copy 
number alterations could be identified by NGS. NGS also has applications for analysis of 
methylation and gene expression. All in all, NGS enables the assessment of a more 
complete picture of the molecular architecture of tumors, which could lead to more 
efficient treatment decisions. 
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